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1 INTRODUCTION 
 
1.1 Resin acids and their history 
 
Conifers are considered one of the oldest plant species found on Earth (Henry 2004). 
The earliest fossil identifiable of conifers dates back to the carboniferous period 
approximately 300 million years ago. The reason of the successful continuation of the 
species is their high evolved defense system which protects them against outer invaders 
(Bohlmann and Croteau 1999; Phillips and Croteau 1999; Langenheim 2004; Huber et 
al. 2004; Martin and Bohlmann 2005; Keeling and Bohlmann 2006). When conifers get 
wounded by herbivores and pathogens, they secret a viscous oleresin as a protection 
mechanism. This oleresin is a mixture of terpenoids consisting of turpentine comprising 
of monoterpenes and sesquiterpenes and rosin comprising of diterpenes. The viscous 
oleoresin traps or thrusts the attacking insects and seals the tree wound from 
microorganisms. The more volatile turpentine of the oleoresin evaporates and the 
remaining non-volatile diterpene resin acids polymerize to form a chemical barrier that 
seals the wound of the tree. 
 
 
Figure 1. Resin of a pine tree, Helsinki. 
 
Pine resin (Figure 1) has been used for several millennia to treat external skin 
conditions including wounds, boils and pyodermas (San Feliciano et al. 1993). In fact, 
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the ancient Egyptians used resin-impregnated linen bandages in mummification during 
the 11th dynasty nearly 4000 years ago (Proefke et al. 1992). That inhibited the insects 
and microbes from destroying the dead tissue. 
 
In Finland, the first publication of the use of resin in medical practice was written by the 
Swedish physician Benedictus Olai in 1578 (Olai 1578). The publication included a 
medical recipe for making a cream to treat old leg wounds as follows: “…take wax and 
white spruce resin, both 2 pellets, rams tallow 2 pellets, ship pitch, and olive oil, both 6 
pellets…keep in glass container. The wound has to be washed three times a day with 
sweet wine, and then spread with the above mentioned salve”. Beside its medical 
benefits, resin has been used in various non-medical applications ranging from religious 
purposes to ship industry (Langenheim 2004). Other products which may include resin 
in their manufacturing are for example paints, lacquers, items of personal hygiene, 
perfumes, chewing gums, soaps and printing inks (Metsälä 2001). 
 
1.2 Terpenes, terpenoids and resin acids 
 
Resin can be defined as a viscous liquid secreted by plants, consisting of volatile and 
non-volatile terpenes as well as essential oils (Langenheim 2004). Terpenes, the major 
components of resin, are made of multiple isoprene units with molecular formula 
(C5H8)n with n being the number of linked isoprene units (Dorman 2000). They are 
classified according to the structural organization of carbons and the number of isoprene 
units. When terpenes are modified chemically, either by oxidation or rearrangement of 
the carbon skeleton, the resulting compounds are generally referred to as terpenoids 
(Keeling and Bohlmann 2006). Similar to terpenes, terpenoids are classified according 
to the number of isoprene units. Conifers produce mostly tricyclic diterpenoids which 
are composed of four isoprene units, i.e., 20 carbons. 
  
Using fractional distillation, the components of resin can be separated to give rosin, 
containing a mixture of different resin acids (Zulak et al. 2010). Resin acids are a group 
of diterpenic carboxylic acids found in the solid portion of tree resins. The basic 
skeleton consists of three fused rings with the empirical formula C19H29COOH 
(Silvestre et al. 2008; Yadav et al. 2015). The resin acids are poorly soluble in water 
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and they have a yellowish gum-like structure. They are mainly classified as abietic-type 
(Figure 2) and pimaric-type resin acids (Figure 3). 
 
 
Figure 2. Examples of abietic-type resin acids. 
 
 
Figure 3. Examples of pimaric-type resin acids. 
 
The resin acids have mainly two reactive centres which can be easily chemically 
modified: the double bonds and the carboxyl group (Yadav et al. 2015). The unique 
bioactive properties of the resin acids make them good candidates for drug discovery. 
 
The numbering of the diterpenoid family was introduced in 1969 by Burgstahlerand and 
Marx, following the synthesis of the fossil resin hydrocarbon fichtelite from 1. 
According to the IUPAC recommendations, the abietane skeleton (Figure 4) was chosen 
as fundamental parent for this family. Abietanes with aromatic ring C and different 
degree of oxygenation are considered the largest group of the naturally occurring 
abietanes (González 2015).  
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Figure 4. The abietane skeleton. 
 
 
1.3 The biological activity of naturally occurring resin acids 
 
Lately the biological activity of resin acids and their effects on human health have 
drawn the attention of many research groups. Studies on the biological activity of resin 
acids showed their antimicrobial, anti-inflammatory, antitumor and anti-diabetic 
properties (González 2015).  Iwamoto et al. (2003) investigated the antitumor properties 
of diterpenoids extracted from the stem bark of Thuja standishii (Gordon) Carrière. The 
study group examined four different diterpenoids in vivo in a two-stage mouse-skin 
carcinogenesis assay. They found that ferruginol, sugiol, isocupressic and 
sandaracopimaric acids exhibited strong antitumor promoting activity. In addition to 
that, antitumour-promoting diterpenoids have been isolated from the stem bark of Picea 
glehnii (F.Schmidt) Mast. (Kinouchi et al. 2000). 
 
Antibacterial activity of some naturally occurring resin acids was studied in vitro using 
disc diffusion on agar, agar dilution and broth dilution methods (Söderberg et al. 1990). 
Examples of resin acids used were dehydroabietic, neoabietic, isopimaric, abietic and 
levopimaric acid. DHAA proved to be the most potent toward gram-positive bacteria. 
Also antibacterial effects of diterpenoids have been studied against the MRSA (Gaspar-
Marques et al. 2006; Oluwatuyi et al. 2004; Fallarero et al. 2013). 
 
In 2005, Smith et al. investigated the activity of AA and isopimaric (IPA) resin acids 
extracted from the immature cones of Pinus nigra J.F.Arnold against different strains of 
S. aureus. The MICs of the resin acids were compared to that of standard antibiotics 
(Table 1) 
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Strain of  
S. aureus 
 
IPA 
 
AA 
 
Teracycline 
 
Norfloxacin 
 
Erythromycin 
 
Oxacillin 
XU212 (TetK)  32  64 128 16 4096    256 
SA-1199B 
(NorA) 
 32  64      0.25 32 0.25    0.25 
RN4220 
(MsrA) 
 4  64      0.25 2 128    0.25 
EMRSA-15  32  64      0.125 0.5 2048    32 
EMRSA-16  64  64      0.125 128 4096    512 
ATCC 25923  64  64      0.25 1 0.25 0.125 
 
Table 1. Minimum inhibitory concentrations (MICs) of IPA and AA compared to that of standard 
antibiotics in µg/mL (adapted from Smith et al. 2005). 
 
Even though IPA and AA displayed activity against all studied S. aureus strains, IPA 
had higher activity against three resistant strains. The MIC value of IPA was 32–64 
µg/mL while for AA it was 64 µg/mL against all tested strains. The study proved that 
IPA is more active.  
 
Another study done by Kopper et al. (2005) investigated the effect of diterpene acids 
against the germination of the pathogenic Ophiostoma ips. AA, DHAA and IPA were 
amended with 2% malt-extract agar. The resin acids were dissolved in acetone and then 
added to the molten agar to give the desired weight percentage. Different concentrations 
of the three diterpene acids were used including 0.1, 0.5 and 1.0%. No 1.0% treatment 
of IPA was used as it was insoluble at this concentration. As controls, blanks (no 
treatment) and acetone were used. Amended agar was allowed to cool in petri dishes for 
24 hours, after which a piece of malt-extract agar colonized with the growing 
Ophiostoma ips was added to the study dishes. AA displayed high activity, as when 
used in 0.1, 0.5 and 1.0%, the germination of Ophiostoma ips was reduced by 39, 30 
and 91%, respectively. The treatments using DHAA yielded the same results as that of 
the control acetone. Only at 0.5% concentration, 26% germination reduction was 
observed lower than what was noticed in the acetone-only treatment. IPA exhibited 
moderate activity reducing the germination in the 0.1 and 0.5% treatments to 43 and 
74% relative to the control treatment, respectively. 
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In a screen for potential therapy against human respiratory syncytial virus (hRSV), Shin 
et al. (2013) studied the biological activity of carnosic acid, a diterpenoid extracted 
from Rosmarinus officinalis L. Effect of carnosic acid on the replication of hRSV was 
determined by microneutralization assay and plaque assay. The acid efficiently 
suppressed the replication of the virus in a concentration-dependent manner. The viral 
gene was successfully suppressed without inducing type-I interferon production or 
affecting cell viability. The research group suggested that carnosic acid directly affected 
viral factors.   
 
Búfalo et al. (2015) studied the biological activity of four diterpenoids extracted from 
the roots of Salvia deserta Schangin. Taxodione, ferruginol, 7-O-acetylhorminone and 
horminone were investigated for their antimicrobial and antileishmanial activity. The 
diterpenoid taxodione exhibited leishmanicidal properties against Leishmania donovani 
with an IC50 value of 0.46 mg/L. In addition, moderate antifungal and antimicrobial 
activities were determined. Ferruginol had the greatest antibacterial activity against 
Streptococcus iniae with an IC50 value of 1.29 mg/L. A crude extract fraction 
containing 7-O-acetylhorminone and horminone exhibited a remarkable antibacterial 
activity against S. aureus with IC50 of 1.3 mg/L. 
 
The anti-inflammatory activity of DHAA isolated from Abies forrestii Coltm.-Rog. was 
studied by Yang et al. 2009 against lipopolysaccharide (LPS) -induced nitric oxide 
production in RAW2647 macrophages. Effect on nuclear factor kappa-light-chain-
enhancer of activated B cell (NF-κB) activities triggered by tumor necrosis factor alpha 
(TNFα) in pNF-κB-luc-293 cells was also studied. Aminoguanidine and tripterygium 
glycosides were used as positive controls. In the inhibitory activities against LPS-
induced NO production in RAW2647 macrophages DHAA exhibited moderate effect 
with IC50 value of 42.7 µg/mL compared to aminoguanidine (3.3 µg/mL). In the other 
anti-inflammatory assay against TNFα-triggered NF-κB activity in pNF-κB-luc-293 
cells, DHAA demonstrated activity with IC50 value of >100 µg/mL compared to 
tripterygium glycosides (1.0 µg/mL).  
 
The effect of DHAA on glucose and lipid metabolism was further investigated using 
obese diabetic KK-Ay mice. Plasma concentrations of obesity-related factors such as 
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monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor alpha (TNFα) 
in the mice were determined using enzyme-linked immunosorbent assay (ELISA) kits. 
An ultrasensitive rat insulin kit was used to measure insulin levels. After a one-week 
adaptation period, the mice were given a high-fat diet containing DHAA (0.1% or 
0.2%). A control group was fed the same diet without DHAA. The experiment 
continued for five weeks. The insulin levels of DHAA-treated mice decreased nearly to 
half compared to the control group. MCP-1 and TNFα decreased in plasma by ~ 60% 
and ~ 25%, respectively, compared with the control group. 
 
2 SAR FOR ANTIMICROBIAL ACTIVITY OF RESIN ACIDS 
 
2.1 Antibacterial activity 
 
The structure-activity relationship (SAR) studies of some resin acids and their 
derivatives showed that they possess antibacterial and antifungal activity (Savluchinske-
Feio et al. 1999). In 2002, Gigante et al. studied several DHAA derivatives bearing 
different stereoconfiguration of A/B ring junction and various functional groups at C-7, 
C-12 or C-18 (Figure 5). Modifications also included the removal of isopropyl group at 
C-13. The compounds were tested against various species of fungi, yeasts and bacteria. 
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Figure 5. DHAA and its modified derivatives synthesized by Gigante et al. 2002. 
 
In the case of bacterial studies, no activity against Gram-negative bacteria was detected 
by the research group (Gigante et al. 2002). The derivatives with hydroxyl or aldehyde 
groups at C-4 showed activity against Gram-positive S. aureus. The activity of the 
derivatives was independent of the presence or absence of the isopropyl group at C-13. 
The stereoconfiguration of the A/B ring junction did not influence activity. The 
presence of a hydroxyl or ketone group at C-7 or C-12 proved to be important for 
antibacterial activity. However, for S. aureus, none of the DHAA derivatives showed 
lower MIC (minimum inhibitory concentration) than the control drug rifampicin. 
 
In 1999, Savluchinske-Feio et al. determined the significance of C-13 isopropyl group 
and C-7 oxygenation on the antimicrobial activity of DHAA derivatives (Savluchinske-
Feio et al. 1999). The group tested the antibacterial activity of six compounds as shown 
in Figure 6. Examples of bacteria used are S. aureus, Enterococcus faecalis, 
Escherichia coli and Klebsiella pneumoniae. 
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Figure 6. Derivatives of DHAA. 25) methyl dehydroabietate, 26) methyl 7-oxodehydroabietate, 27) 
methyl cis-deisopropyldehydroabietate, 28) methyl trans-deisopropyldehydroabietate, 29) methyl cis-7-
oxodeisopropyldehydroabietate, 30) methyl trans-7-oxodeisopropyldehydroabietate (adapted from 
Savluchinske-Feio et al. 1999). 
 
The antibacterial studies showed that compounds 29 and 30 inhibited the growth of 
Gram-positive bacteria when tested separately. When tested together, both compounds 
were able to inhibit the growth of Gram-negative bacteria. Compounds 25 and 27 did 
not show any anti-bacterial activity while 26 and 28 showed low activity against Gram-
positive bacteria. The study showed that the stereochemistry of the A/B ring junction of 
the molecule did not influence the degree of activity. Moreover, the C-13 isopropyl 
group proved to be unnecessary for the biological activity whereas oxygenation at C-7 
proved to be important for the activity. The results were compatible with the findings of 
Gigante et al. 2002. 
 
In 2010, Gu and Wang introduced a carbazole moiety to DHAA and succeeded in 
synthesizing series of novel 1H-dibenzo[a,c]carbazole derivatives (Figure 7). The 
activity of the synthesized compounds was tested against two Gram-positive bacteria 
(Bacillus subtilis, Staphylococcus aureus), two Gram-negative bacteria (Escherichia 
coli and Pseudomonas fluorescens) and three fungi (Trichophyton rubrum, Candida 
albicans and Aspergillus niger). 
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Figure 7. Carbazole derivatives of DHAA (adapted from Gu and Wang 2010).  
 
The MIC values of the tested compounds were determined. For the antibacterial studies, 
the antibiotic amikacin was used as a reference compound, while for the antifungal 
studies, ketoconazole was used. The majority of the study compounds exhibited 
biological activity. Compounds 34, 36 and 43 showed strong activities toward B. 
subtilis and S. aureus. Compound 34 showed the most robust activity against Gram-
positive B. subtilis and the Gram-negative P. fluorescens with MIC values of 1.9 µg/ml 
and 7.8 µg/ml, respectively, compared to that of amikacin (0.9 µg/ml). 
 
Most of the compounds showed low antifungal activity except for 35 and 43 which 
showed moderate inhibition with MIC values of 31.2-62.5 µg/mL and 62.5-> 100 
µg/mL, respectively. The reference compound ketoconazole had a MIC value of 3.9 
µg/mL. 
 
The SAR studies of the compounds indicated that the introduction of carbazole moiety 
to the methyl dehydroabietate enhanced the biological activity. Also the activity of the 
derivatives was influenced by the aromatic substitution. Electron-withdrawing 
substituents such as F, Cl and NO2 in the aromatic ring resulted in higher activity 
against the tested bacteria than the electron-donating ones. 
 
 
11 
 
2.2 Antiparasitic activity 
 
In a research done by Vahermo et al. (2016), 31 DHAA derivatives (Figure 8) bearing 
different amino acids were tested for antiprotozoal activity against Leishmania 
donovani and Trypanosoma cruzi. The tested compounds included DHAA, an amide 
derivative, and other derivatives synthesized by coupling ring A of the diterpenoid core 
of DHAA with L- and D-amino acids. The antifungal drug amphotericin B was used as a 
positive control. 
 
 
Figure 8. DHAA derivatives synthesized by Vahermo et al. 2016 (Vahermo et al. 2016). 
 
The activity of the compounds was measured at a concentration of 50 µM. Compounds 
showing significant activity at this concentration were further assayed at 15 µM and 5 
µM. The study showed that compounds bearing aliphatic amino acids were moderately 
12 
 
active at a concentration of 50 µM. Derivatives carrying aromatic amino acids inhibited 
the growth of the parasites by more than 70% at the same concentration. Activity of the 
compounds bearing the bulky, non-aromatic cyclohexyl-L-alanine side-chain was 
observed at 50 µM. 
 
When tested at lower concentrations, none of the derivatives bearing a small aliphatic 
side-chain retained activity, indicating that the size of the side-chain is important for the 
activity. The best antileishmanial compounds were the derivatives of cyclohexyl-L-
alanine.  
 
Overall, the antiprotozoal activity of the synthesized compounds relies greatly on the 
size of the side chain, its aromaticity and amphipathicity. Also, all, but one, of the active 
compounds had a free carboxyl group, indicating its importance. 
 
2.3 Antifungal and antiviral activity 
 
In another study, catechols prepared from AA were evaluated for antifungal and 
antiviral activities (Gigante et al. 2003). The activity of AA derivatives (Figure 9) were 
compared to that of carnosic acid, a naturally occurring catechol with antiviral activity. 
  
 
Figure 9. AA derivatives 75-78 possess a skeleton and an aromatic moiety similar to the naturally 
occurring catechol carnosic acid (adapted from Gigante et al. 2003). 
 
Compounds 75-79 were screened for their biological activity against different fungal 
species including Candida albicans, Candida glabrata, Cryptococcus neoformans, the 
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mold Aspergillus fumigatus, the dermatophytes Microsporum canis, Trichophyton 
mentagrophytes and Epidermophyton floccosum. All the compounds exhibited activity 
against dermatophytes but no activity was detected against C. albicans, C. glabrata, C. 
neoformans and A. fumigatus. Catechols 75 and 78 proved to be the most active 
showing a potent activity greater than the antifungal agent fluconazole.  
 
Antiviral activity against herpes simplex virus 1(HSV-1), herpes simplex virus 2 (HSV-
2), vaccinia virus (VAC) and African swine fever virus (ASFV) were tested for 
compounds 75-79. The synthetic catechol 75 proved to be the most active. The study 
showed that tricyclic diterpenes with catechol moiety are an interesting group of 
compounds that exhibit biological activity. 
 
3 BACTERIAL BIOFILMS 
 
3.1 Overview 
 
In recent years, bacterial infections became a serious threat due to the high resistance 
bacteria exhibit towards conventional antibiotics (Toté et al. 2009; Melchior et al. 2006; 
Girard et al. 2010). Bacterial biofilm (Figure 10) is a lifestyle where bacteria attach to a 
surface and grow as a community in a self-produced thick layer of extracellular 
polymeric substances. The physical architecture of biofilms is different from that of 
single-cell bacteria which explains the difference in their functional behaviour. The 
biofilm matrix protects the bacteria from chemical and physical stresses making them 
resistant to conventional antimicrobial therapy. 
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Figure 10. Atomic force and scanning electron microscopy images of S. aureus biofilms (Ausbacher et 
al. 2014). 
  
Biofilm development is divided into three phases (Figure 11): attachment, maturation 
and detachment (Otto 2013). The bacteria can attach to a surface or to a film formed by 
host matrix molecules. After attachment, bacteria cells link together and proliferate in a 
process known as maturation. Bacteria form channels in the biofilm structure through 
which necessary nutrients can reach deeper cells. Finally, the cells from the biofilm 
colony disperse, spread to new surfaces and colonize. 
 
Figure 11. Phases of biofilm development (Otto 2013). 
 
In 1999, Ceri et al. studied the susceptibility of S. aureus (ATCC 29213) biofilms to 
seven different antibiotics. The MIC and the minimal biofilm eradication concentration 
(MBEC) were determined using two assay techniques: Calgary Biofilm Device (CBD) 
and National Committee on Clinical Laboratory Standards (NCCLS) method (Table 2). 
The research group defined MBEC as the minimal concentration of antibiotic needed to 
eliminate the biofilm.  MIC was defined as the lowest concentration of antibiotic needed 
to prevent the biofilm formation by shedding planktonic bacterial population. 
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Antibiotic             MIC (µg/ml)          MBEC (µg/ml) 
 NCCLS 
assay 
Assay with 
CBD 
NCCLS 
Assay 
Assay with 
CBD 
Cefazolin 0.5 0.5 > 1.024 > 1.024 
Ciprofloxacin 0.25 0.5 512 512 
Clindamycin 0.12 0.25 128 256 
Gentamicin 0.5 0.5 2 2 
Oxacillin 0.12 0.25 > 1.024 > 1.024 
Penicillin 1 4 128 128 
Vancomycin 1 1 > 1.024 > 1.024 
 
Table 2. Antibiotic susceptibility of planktonic (MIC) and biofilm (MBEC) S. aureus using NCCLS and 
CBD assay methods (adapted from Ceri et al. 1999). 
 
The study proved that formed biofilms require from 100 to 1000 fold higher amounts of 
antibiotics than what was needed for planktonic population to achieve MIC. Only 
gentamicin, an aminoglycoside, showed activity against the biofilm of S. aureus. 
 
Biofilms are the cause of a broad range of infections including urinary and respiratory 
tract infections as well as medical device-associated infections (Yan et al. 2013). From 
a basic research perspective, the number of effective compounds that can be currently 
used as chemical tools to explore biofilms behaviour is limited. 
 
Methicillin-resistant staphylococcus aureus (MRSA) is a bacterium strain which causes 
severe infections in humans (McDougal et al. 2003). This strain of S. aureus developed 
resistance to β-lactam antibiotics, such as penicillins, which makes the infection 
difficult to treat. Multi-drug resistant (MDR) strains of S. aureus have a pump in their 
cytoplasmic membrane which they use to efflux antibiotics and antiseptics out of the 
cell (Marshall and Piddock 1997). These epidemic strains are mainly a problem in 
hospitals especially for patients with compromised immune systems. S. aureus 
colonizes mainly in the respiratory and urinary tracts, intravenous catheters and open 
wounds (Yan et al. 2013). The risk factor groups are the elderly, people with weak 
immunity, health care workers and diabetics. Healthy people can carry MRSA and be 
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asymptomatic from a period of few weeks to years. Compounds with activity against 
MRSA are desperately needed to treat virulent biofilm-mediated infections. 
 
3.2 Antibiotic resistance in bacterial biofilms 
 
Bacterial biofilm infection is very persistent in the body and can remain for months or 
even years (Stewart and Costerton 2001). In 1981, a 56-year old male with a pacemaker 
was admitted to the hospital with a 4-day history of shaking chills, vomiting, fever and 
nausea (Marrie et al. 1982). When examining his blood cultures, S. aureus was found. 
The treatment went on for 4 weeks by administrating 12 g of cloxacillin daily. One 
week after the man was discharged, he exhibited the same symptoms he had before and 
was taken back to the hospital where it was found that S. aureus grew again from his 
blood cultures. Intravenous cloxacillin (12 g) and oral rifampicin (600 mg) were 
administrated daily for six weeks. Nine days after discharge the man was readmitted to 
the hospital with the same symptoms and S. aureus grew from blood cultures. The 
infection of the patient was caused by bacterial biofilm of S. aureus growing on the 
pacemaker and causing endocarditis. Once the entire pacemaker was removed and 
cloxacillin was given for four weeks, the man was free from infection. 
 
The mechanism by which biofilms become resistant to antibiotics is not acquired via 
mutations or mobile genetic elements (Stewart and Costerton 2001). In 1996, Stewart 
suggested that the resistance can be possibly due to the incomplete or slow penetration 
of antibiotics through the biofilm (Stewart 1996). Moreover, if the antibiotics adsorp 
into the biofilm matrix, they would have a retarded penetration (Shigeta et al. 1997). 
For example, the positively charged aminoglycosides bind to the negatively charged 
polymers found in the matrix of the biofilm. This might account for their slow 
penetration. 
 
A second hypothesis states that the altered chemical microenvironment within the 
biofilm is the reason of the resistance (De Beer et al. 1994). A study by De Beer et al. 
(1994) showed that oxygen is entirely consumed on the surface of the biofilm. This 
leads to anaerobic niches deep into the biofilm layers and pH differences between the 
surface of the biofilm and its interior. Tack and Sabath (1985) tested the efficacy of 
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aminoglycoside antibiotics against the same microorganisms in aerobic and anaerobic 
conditions. The study showed that the antibiotic was considerably less effective in the 
anaerobic conditions. 
 
Another mechanism of resistance could be the ability of a subpopulation of the biofilm 
to enter a spore-like state and become biologically inactive under chemical and 
environmental stresses (Stewart and Costerton 2001). This indicates that most of the 
biologically active planktonic bacteria in the biofilms are killed by antibiotics and only 
a small portion survives. After the termination of the antibiotic treatment, persisters 
convert from dormancy to a growing state and start regrowing the biofilm (Brooun et al. 
2000). This hypothesis can help explain the condition of the patient with pacemaker 
endocardidits mentioned above. As after each hospitalization and intensive antibiotic 
administration, the patients felt well and got released, indicating that a large portion of 
the bacteria was killed.  It took only a few days for the patient to become rehospitalized 
because of the same symptoms. This represents the time needed by the super resistant 
cells to regrow the biofilm and for the symptoms to reappear. 
 
More investigations are needed to fully understand the resistance mechanism(s) of 
biofilms. It is highly likely that the resistance is caused by the combination of multiple 
mechanisms. As mainly the biofilm resistance is due to the bacterial aggregation, drugs 
that can disrupt the multicellular structure of the biofilm are urgently needed. Once 
disrupted, the resistance will decrease and the efficacy of conventional antibiotics may 
be restored. 
 
3.3 The anti-biofilm activity of DHAA 
 
Fallarero et al. (2013) studied the effects of ten abietane-type diterpenes against 
biofilms formed by S. aureus. The study included nordehydroabietylamine, (+)-DHAA, 
(+)-dehydroabietylamine and seven other urea derivatives. The anti-biofilm activity was 
examined through a screening platform developed by the research group. Compounds 
were added before or after biofilms were formed and effects on viability were measured 
using reliable assay methods. 
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The study proved that nordehydroabietylamine, (+)-DHAA and (+)-
dehydroabietylamine prevented biofilm formation significantly and acted on the formed 
biofilms with potencies in the micromolar range. To ensure that the anti-biofilm effect 
of the three compounds was not due to non-specific cytotoxicity, cytotoxicity assays 
were performed with three different cell lines (HL, HepG2 and GT1-7). 
Nordehydroabietylamine and (+)-DHAA caused more than 50% cell death while (+)-
DHAA was the most tolerated compound. 
 
In another study targeting planktonic and biofilm S. aureus bacteria, a new class of 
DHAA derivatives was discovered (Manner et al. 2015). In the research, different 
amino acids were combined with DHAA to produce hybrid compounds that are 
significantly more potent anti-biofilm agents than conventional antibiotics. The 
compounds were able to compromise the integrity of the bacterial membrane in a short 
period of time and in very low concentrations. 
 
Based on the antibacterial information mentioned above, DHAA represents a good 
candidate for drug discovery. The compound and its derivatives showed significant 
activity as antimicrobial agents. In addition to that, the molecule of DHAA is 
chemically stable. This allows different chemical modifications and a potential for 
reaction scale-up. When compared to other resin acids, Fallarero et al. (2013) proved 
that DHAA is the less toxic, proving its selectivity. 
 
4 THE AIM OF THE STUDY 
 
The aim of this study was to synthesize antimicrobial and anti-biofilm agents using 1 
and 3. Bacterial biofilms are formed where bacterial cells cluster together within a self-
produced extracellular matrix and become highly resistant to conventional antibiotics. 
 
Potent drugs are urgently needed to counteract biofilm infections of Gram-positive 
bacteria. In addition, basic in vitro and in vivo studies to explore the behavior of 
biofilms need anti-biofilm agents as a chemical study tool. 
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Specific chemical modifications modulate the antimicrobial activity of resin acids. In 
this thesis, molecular design was done based on the information gathered about the 
structure-activity relationships of 1 and 3. Most of the synthesized compounds possess a 
free carboxyl group on ring A. In two chain reactions, a hydroxyl group was added to 
C-12. Other modifications included the oxidation of C-7. No reaction was done on the 
isopropyl group at C-13. 
 
The amino acid β-cyclohexyl-L-alanine was specifically chosen for the designed 
reactions as Manner et al. (2015) proved its activity when coupled with DHAA. 
Furthermore, compounds based on this amino acid proved to be non-cytotoxic when 
tested against human HL cells.  
 
The compounds are designed to have an optimal balance of hydrophobicity achieved by 
the presence of cyclohexyl-based side-chain and hydrophilicity, conferred by the 
presence of an additional hydroxyl or carbonyl groups. The design of appropriate 
synthetic routes was done using chemical literature and reaction databases. The 
compounds were further studied by elucidating and confirming their chemical structures 
by spectroscopic methods. 
 
5 RESULTS AND DISCUSSION 
 
5.1 Modification of ring A 
 
The first set of compounds shown in Scheme 1 was synthesized by coupling 3 with 
methyl ester hydrochlorides of β-cyclohexyl-L-alanine (80), D-tryptophan (82), L-
leucine (84) and ( ̶ )-2-aminobutyric acid (86) as reported in the literature (Manner et al. 
2015). 
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Scheme 1. Syntheses of compounds 80 to 87. 
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1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride was used as a 
coupling agent while N,N-Diisopropylethylamine (DIPEA) was used as a base. The 
main function of hydroxybenzotriazole (HOBt) is to improve the reaction efficiency. 
Carboxylic acid derivatives were synthesized from esters by alkaline hydrolysis using 4 
M NaOH.  
 
Two centres of reactivity exist in the carbodiimide molecule; the terminal nitrogens are 
electron-rich and the central carbon atom is electrophilic (Williams and Ibrahim 1981). 
In EDC coupling, carbodiimide reacts with the carboxylic acid and O-acylisourea mixed 
anhydride is yielded (Mechanism 1). This intermediate reacts with amine to form the 
wanted amide. The reaction also yields the corresponding urea as a by-product.  
 
 
Mechanism 1. The use of EDC and HOBt to yield an amide bond (adapted from Williams and Ibrahim 
1981). 
 
Often acyl transfer can result in the formation of non-reactive N-acylurea from O-
acylisourea (Mechanism 2). This side reaction can be diminished by adding a selected 
nucleophile that reacts faster than the acyl transfer and is able to generate an 
intermediate active enough to couple with the amine. Example of this nucleophile is 
HOBt. 
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Mechanism 2. The formation of unreactive N-acylurea in the absence of HOBt. 
 
Overall, the synthetic routes were reproducible. The methyl ester derivatives were 
purified by column chromatography and the yields presented are after purification. As 
Manner et al. (2015) proved that the presence of a free carboxyl group on ring A is 
important for the biological activity, methyl esters were converted to their relative acids. 
Analytical techniques showed that the acid derivatives were within the purity criteria 
after the work up and there was no need for further purification. 
 
The goal of preparing these compounds was to get acquainted to the work in the organic 
chemistry laboratory and to get introduced to the chemistry of resin acids. The EDC 
coupling reaction was further applied to synthesize the novel compounds of this thesis. 
 
5.2 Modification of ring B 
 
In order to explore new modifications of the diterpenoid scaffold, ring B was targeted. 
As previously mentioned, the presence of ketone carbonyl group on C-7 of DHAA 
proved to be important for antibacterial activity (Gigante et al. 2002; Savluchinske-Feio 
et al. 1999). 
 
As the first approach, the lactam derivative of DHAA was synthesized as described in 
the literature (Tashima et al. 2006). Then it was coupled to β-cyclohexyl-L-alanine 
methyl ester according to the procedure of Manner et al. (2015). Finally, the free 
carboxylic acid derivative was synthesized to yield compound 95 as a final product. 
Compounds 94 and 95 are new and have not been reported in the literature before. 
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Scheme 2. Synthesis of the lactam derivative compound 95. 
 
The first step of the synthesis was the methylation of 3 (Jeong et al. 2007). The 
commercially available 3 was reacted with methyl iodide and potassium carbonate in 
N,N-dimethylformamide at rt to give compound 88, in 88% yield (Scheme 2). The 
benzylic oxidation of compound 88 was made according to the procedure of Manner et 
al. (2015) with CrO3 in EtOAc / AcOH, at 50 °C to give 89, in 45% yield. The moderate 
yield obtained from this reaction is due to the formation of an unwanted side product 
which consumed a fair amount of the starting material 88. The ketone 89 was reacted 
with hydroxylamine hydrochloride in EtOH / pyridine at 100 °C to produce the oxime 
90, in 97% yield (Tashima et al. 2006). The oxime derivative was further tosylated 
using TsCl in pyridine at rt to give 91, in 38% yield (Scheme 2). In the reported 
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procedure, no work-up was done for 91 after the reaction was completed. The resulting 
residue was directly purified by flash chromatography and the yield was 96%. Upon 
following this procedure, a mixture of TsCl and 91 was obtained. To remove TsCl, a 
work-up was done using water, a saturated aqueous solution of sodium bicarbonate and 
brine after which the product was dried with sodium sulphate and evaporated to dryness 
to yield 38% of pure 91. The work-up of the reaction mixture before purification with 
flash chromatography proved to be important and might be a good aid to improve the 
yield. 
 
The lactam derivative 92 was synthesized by the Beckmann rearrangement of 
compound 91, the tosylated oxime (Tashima et al. 2006). The reaction was done in the 
presence of trifluoroacetic acid at rt to give compound 92, in 97% yield. Using KOH 
and 18-crown-6 in methanol, compound 92 was hydrolyzed, at 80 °C, to give the 
corresponding carboxylic acid 93, in 59% yield (Scheme 2). 
 
The carboxylic acid 93 was coupled to β-cyclohexyl-L-alanine using EDC.HCl as a 
coupling agent at rt to provide 94, in 57% yield. Finally compound 94 was hydrolyzed 
at rt using 4 M NaOH to give 95, in 73% yield. Overall, the synthesis of 95 was 
successful. 
 
The Beckmann rearrangement is the key step responsible for the lactam formation from 
the cyclic oxime (Gawley 1988; Ronchin et al. 2008). First, the oxime oxygen is 
protonated by trifluoroacetic acid and H2O+ is formed. Protonated water is a better 
leaving group than OH (Mechanism 3). This is followed by the attack of the 
neighbouring C-C bond on the nitrogen to form a new C-N bond displacing the water as 
a leaving group. The base deprotonates the positively charged oxygen and the tautomer 
of the amide is yielded, after nitrogen protonation and oxygen deprotonation. 
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Mechanism 3. Beckmann rearrangement of oxime to lactam (adapted from Gawley 1988). 
 
The structure of the novel compound 95 has been confirmed by IR, NMR and UPLC-
HRMS. Figure 12 shows the IR spectrum of compound 95. According to Hase (2008), 
the N-H stretching appears between 3310-3350 cm-1 as a broad peak. In the IR spectrum 
of 95 the N-H peak appears at 3347 cm-1. The medium peak at 2956 cm-1 is due to the 
alkyl C-H stretch. 
 
The C=O stretch is considered one of the strongest IR absorptions. Two strong peaks 
appear at 1742 and 1638 cm-1 which plausibly results from the carbonyl stretches C=O. 
Even though the molecule has three carbonyl groups of the carboxylic acid, the lactam 
and the amide group, two of them must be superimposed as only two peaks appear. 
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Figure 12. IR spectrum of compound 95. 
 
 
Figure 13. 1H NMR spectrum of compound 95. 
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Figure 13 represents the 1H NMR spectrum of 95 where the most characteristic peaks of 
the compound are presented. Based on the values of the chemical shifts stated by Hase 
(2008), the one proton singlet which appears at 8.70 ppm is due to the absorption of a 
proton attached with a nitrogen atom in a saturated heterocyclic ring. Three signals exist 
in the aromatic region. Two peaks are doublets showing at 7.30 and 7.01 ppm while the 
third is singlet at 6.75 ppm. Each peak is formed by a single proton and they represent 
the protons of the aromatic ring. The doublet at 6.38 ppm results from the proton 
attached to the amide nitrogen as only an electronegative group can shift the signal 
downfield. A one-proton quartet at 4.60 ppm is due to the absorption of an aliphatic 
proton attached to electronegative groups. This proton is the one existing between the 
amide group and the carboxyl group. The proton is split into quartet by the protons of 
the adjacent groups CH2 and NH. The carboxyl group has an exchangeable proton 
which does not appear in this spectrum. Hase (2008) stated that the exchangeable proton 
of COOH is found between 9-13 ppm. 
 
 
Figure 14. 13C NMR of compound 95. 
 
The 13C NMR spectrum (Figure 14) designates the presence of three carbonyl groups at 
177.5, 177.0 and 176.4 ppm. The three C=O groups are that of the lactam ring, carboxyl 
28 
 
group and amide group respectively (Hase 2008). The aromatic region between 148.0-
121.1 ppm contains six peaks corresponding to the aromatic carbons. The rest 20 
carbons are aliphatic and can be found between 50.7-16.8 ppm. The values on the 
molecule (Figure 14) are estimated based on the presence of adjacent electronegative 
groups and the values given by Hase (2008). 
 
5.3 Modification of ring C 
 
Gigante et al. (2002) proved that presence of a hydroxyl group on C-12 improved the 
antibacterial activity of DHAA. Inspired by the study compounds 98 and 101 were 
synthesized following literature (Manner et al 2015; Thommen et al. 2013). 
Compounds 88 and 80 were synthesized as mentioned previously (Schemes 1 and 2). 
They were reacted with acetyl chloride and aluminium chloride in dichloromethane to 
produce 96, in 89% yield and 99, in 69% yield, respectively (Schemes 3 and 4). The 
synthesis of 96 was completed in 1 hour 15 minutes and the yield was relatively good. 
Compound 99 reacted slower and after 24 hours, starting material was still present. 
More reactants were added and the reaction mixture was stirred at rt for 5 hours 30 
minutes and then warmed at 35 °C for one hour. The boiling point of dichloromethane 
is 39.6 °C, which has been the main reason to warming up. The yield obtained was 
satisfactory but it could possibly be improved by heating the reaction to higher 
temperatures. To increase the heating temperature, dichloromethane can be replaced 
with other similar solvents with higher boiling point such as chloroform (61.15 °C) or 
1,2-dichloroethane (84 °C). 
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Scheme 3. Synthesis of compound 98 from DHAA.  
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Scheme 4. Synthesis of compound 101 from DHAA.   
 
The acylated derivatives 96 and 99 were further oxidized using peracetic acid (36-40 
wt.%) in AcOH to give 97, in 88% yield (Scheme 3), and 100, in 85% yield (Scheme 4) 
(Thommen et al. 2013). The reaction time in both cases was four days and could 
possibly be accelerated by heating or by using a more reactive oxidant than peracetic 
acid. 
 
Conversion of 99 into 100 was also tried using m-chloroperoxybenzoic acid (2 equiv.) 
and p-toluenesulphonic acid (0.083 equiv.) in 1,2-dichloroethane according to Zhou et 
al. 2013. The reaction mixture was refluxed at 83 °C for six days but did not succeed. 
The reason could be the inactivity of the m-chloroperbenzoic acid, as when it was tested 
with a simple test reaction, it did not seem to react. It is possible that the reagent has 
decomposed during the storage. 
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Basic hydrolysis of 97 using 1 M NaOH in MeOH gave 98, in 64% yield. Another 
attempt was made to hydrolyze 97 to 98 using NaOMe in MeOH, at rt, for 1 hour 30 
minutes, which yielded only 46% of the desired product (Thommen et al. 2013).  
 
Despite the fact that DHAA t-butyl ester is a good intermediate for many reactions, an 
efficient way to synthesize it is still required. The DHAA methyl ester, compound 88, 
was easier to synthesize, in 88% in yield, which makes it the current intermediate of 
choice. 
 
The t-butyl ester is considered as a unique protecting group as it is resistant to 
nucleophilic attacks and easily removed by strong acid when compared to methyl ester 
(Wright et al. 1997). Isobutylene gas is the main reagent used in synthesizing t-butyl 
esters. As this gas was not available, it was generated in situ using H2SO4 and t-butyl 
acetoacetate (Scheme 6) as mentioned in the literature by Taber and colleagues (2006).  
 
 
Scheme 5. Synthesis of dehydroabietic acid t-butyl ester 102. 
 
In an attempt to increase the yield, another procedure was tried to synthesize 102 
according to Wright et al. (1997). The group used t-butyl alcohol as an isobutylene 
source in the presence of an acid catalyst. This reaction produces water as a by-product 
and therefore anhydrous magnesium sulphate was used as a dehydrating agent to help 
driving the reaction forward. 
 
The experiment included the addition of H2SO4 to a stirred mixture of anhydrous 
magnesium sulphate in DMF. After this, the DHAA and t-butanol were added and the 
reaction was left to agitate for additional 96 hours. TLC analysis revealed that no 
reaction occurred at any point, indicating the failure of the reaction. Even though the 
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reaction vessel was tightly sealed, isobutylene gas may have escaped the reaction 
container without reacting. 
 
The mechanism behind these reactions, presented in Schemes 3 and 4, is adapted from 
Dakin oxidation (Li 2014). The Dakin reaction allows the preparation of phenols from 
aryl aldehydes or ketones through oxidation with hydrogen peroxide and a base catalyst. 
The carbonyl group of the aryl is oxidized and hydrogen peroxide is reduced. 
 
Mechanism 4 presents the Dakin oxidation in six main steps. The reaction begins with 
the nucleophilic addition of hydroperoxide anion to the carbonyl carbon. As a result, a 
tetrahedral intermediate is formed (Step 2). As shown in Step 3, the unstable 
intermediate collapses and causes [1,2]-aryl migration followed by hydroxide 
elimination and finally,  phenyl ester formation. The phenyl ester is then hydrolyzed 
and a second tetrahedral intermediate is formed. Step 4 shows the intermediate 
formation by the nucleophilic addition of hydroxide ion to the ester carbonyl carbon. 
Then the intermediate collapses (Step 5) and eliminates a phenoxide and a carboxylic 
acid. The phenoxide takes the acidic hydrogen from the carboxylic acid to form the final 
hydroxylated product. 
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Mechanism 4. Dakin oxidation mechanism (adapted from Li 2014).  
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The work presented in scheme 3 was a study done to proceed to the work in scheme 4. 
Compound 101 is a novel compound and has not been reported in literature. The 
chemistry done in the synthetic sequence was first practised by synthesizing 98.  
 
Compound 98 can be used as an intermediate for the discovery of new compounds. 
Protection of hydroxyl group of ring C can be done by following the procedure of 
Thommen et al. (2013). Potassium carbonate and dimethyl sulfate in acetone were used 
to produce methyl ether on C-12. The carboxyl group of ring A can be deprotected as 
reported in literature by Zhou et al. (2010). The group reacted potassium hydroxide 
with DHAA derivative in a mixture of 10:1 ethylene glycol:water, at 120 °C. Another 
option is to follow the route used in the syntheses of compound 93 as previously 
mentioned (Tashima et al. 2006). The protection of hydroxyl group and the deprotection 
of carboxyl group would allow further structure modifications such as nitration, 
halogenation or various addition reactions. 
 
The structure of 101 has been confirmed using IR, NMR and UPLC-HRMS. Figure 15 
represents the IR spectrum of 101. The signals at 2925 (strong) and 2855 (medium)   
cm-1 represent the alkyl C-H stretch (Hase 2008). A strong signal at 1720 cm-1 is 
characteristic for C=O stretch. As 101 has two carbonyl groups in its molecule, they 
must be superimposing. The O-H of carboxyl group usually appears at 3000-2500 cm-1 
as a broad signal, which is not clearly defined in this spectrum. Aromatic C=C bending 
appears at 1626 cm-1 as a medium signal. 
    
34 
 
29
24
.5
3
28
54
.9
0
17
20
.2
6
16
25
.9
5
15
09
.4
6
14
46
.2
3
14
17
.5
1
13
81
.7
1
13
25
.7
9
12
08
.9
1
10
14
.2
4
88
6.
34
73
5.
95
66
8.
44
100015002000250030003500
Wavenumber cm-1
80
85
90
95
10
0
Tr
an
sm
itt
an
ce
 [%
]
 
Figure 15. The IR spectrum of compound 101. 
 
 
Figure 16. 1H NMR spectrum and molecule structure of compound 101.  
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Two singlets, resulting from one proton each, can be seen in the aromatic region (Figure 
16) at 6.81 and 6.62 ppm. The proton closer to the hydroxyl group is shifted more 
downfield than the other one. A one-proton doublet shows at 6.11 ppm. It is the proton 
of the amide nitrogen. The nitrogen proton is split into doublet by the adjacent CH 
group. A one proton peak appears at 4.62 ppm. The CH group adjacent to the NH group 
forms this signal which is split into quartet by the protons of NH and CH2.  
 
Figure 17. 13C NMR spectrum of compound 101. 
 
The 13C NMR spectrum of 101 is presented in Figure 17. The two peaks at 179.1 and 
177.0 ppm correspond to a carbon in a carbon-oxygen double bond (Hase, 2008). Since 
oxygen is more electronegative than nitrogen, in principle, the carbon in the carboxyl 
group will shift more downfield than the carbon in the amide group. Six carbons appear 
in the aromatic region 150.8-110.8 ppm. Values of each aromatic carbon have been 
estimated (Figure 17) based on the chemical environment for each carbon, the presence 
of adjacent electronegative groups and the values provided by Hase (2008). 
 
Compound 100 was converted to 101, using 4 M NaOH in THF:MeOH 1:1, in 98% 
yield. This reaction pathway showed that the amino acid side chain can be attached to 
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DHAA before ring C modification. The other synthetic route possible for 101 would 
involve the deprotection of the carboxylic acid 98 for the coupling of β-cyclohexyl-L-
alanine methyl ester. The ester can be converted to its parent carboxylic acid through 
base hydrolysis. On one hand, using 80 as a starting material of 101 resulted in a 
synthesis route with fewer step reaction than using 88 as a starting material. On the 
other hand, the amino acid coupled to 3 should be chosen so that it does not interfere 
with the ring C modification. D-Tryptophan methyl ester and L-phenylalanine methyl 
ester are examples of amino acids with a benzene ring in their structures. These amino 
acids might not be suitable candidates to be coupled with DHAA before ring C 
modification. The benzene ring in their structure can react in the Friedel-Crafts 
acylation step forming unwanted side products. For instance, the methyl esters of ( ̶ )-2-
aminobutyric acid, valine or leucine represent good candidates for similar reaction as of 
101. 
 
5.4 Other modifications  
 
5.4.1. Hydrogenation of abietic acid 
 
The hydrogention of 1 (Scheme 5) using H2 and Pd/C in MeOH gave 103 (Falorni et al. 
1999). The crude yield before column purification was 95% and after purification it was 
13%. Compound 103 does not absorb UV light and its detection after purification using 
TLC analysis with UV detection was a challenging task.  
 
 
Scheme 6. Hydrogenation of AA to synthesize 23.  
 
Even though the mixture was filtered once through Celite to remove the catalyst, it was 
still detected in the compound after filtration, which explains the high yield before 
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purification. Moreover, the AA used in this reaction is ~75% pure, indicating that 
approximately 25% of the starting material consisted of substances other than AA. 
 
Compound 103 represents a good intermediate for chemical reactions as the saturation 
of the double bonds of the cyclohexenes results in a more stable structure. In general, 
catalytic hydrogenation is a clean reaction and only requires a simple work-up. Using   
> 95% pure AA and filtering through Celite more than once, followed by a MeOH wash 
3-4 times might result in a pure compound without any further silica column 
purification and a better yield. 
 
5.4.2. Chlorination of DHAA 
 
Electrophilic aromatic halogenation is a standard reaction used to synthesize active 
molecules for pharmaceutical and industrial products (Mahajan et al. 2012). Some 
antibiotics which act by inhibiting cell wall synthesis in Gram-positive bacteria carry a 
halogen functionality. Examples of these antibiotics are vancomycin, dicloxacillin and 
cloxacillin. 
 
Several methods have been reported in literature for the chlorination of aromatic 
compounds (Mahajan et al. 2012; Gu et al. 2013). Gu and colleagues (2013) reported a 
procedure for dichlorination of aromatic compounds using a metal-free system. The 
group used saturated aqueous sodium chloride solution as chlorine source and 
potassium persulfate as an oxidant. Chlorination of DHAA (Scheme 7) was done 
according to the procedure of Gu et al. (2013). 
 
 
Scheme 7. Chlorination of 3 following the procedure of Gu et al. (2013) and Mahajan et al. (2012).  
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DHAA was dissolved in acetonitrile. K2S2O8 and brine were added and the mixture was 
tightly sealed and stirred for 3 hours at 100 °C. After the work-up, the residue was 
purified by column chromatography and analysed by NMR. Even though TLC analysis 
showed the compound as one spot, 1H NMR showed the product to be a mixture of 
DHAA and other unidentified compounds. 
 
 
Another dichlorination attempt was done following the procedure of Mahajan et al. 
(2012) as shown in Scheme 7. DHAA, H2O, NaCl, p-TsOH and N-chlorosuccinimide 
(NCS) were added to a round-bottom flask and the mixture was left to agitate, at 40 °C, 
for 4 hours. The reaction was then stopped by the addition of H2O, filtered and dried 
under vacuum. 1H NMR revealed that no reaction happened. 
 
These two chlorination procedures where particularly chosen as the chemistry was done 
on aromatic compounds. Also, the yields reported were good. In spite of this, none of 
them worked and a new procedure is needed for synthesizing chlorinated DHAA 
derivatives.  
 
6 CONCLUSIONS 
 
Biofilms are highly tolerant to conventional antibacterial treatment and withstand from 
100 to 1000 times higher concentrations of antibiotics compared to single cell bacteria. 
This is due to the collective lifestyle of bacteria which makes them highly resilient to 
various environmental and chemical stresses.  
 
Staphylococcus aureus is a Gram-positive bacterium which is responsible for a range of 
human illnesses from minor infections to life-threatening diseases. Recently, the focus 
of the literature has been dedicated to methicillin-resistant S. aureus (MRSA). This 
health threatening strain possesses the ability to switch to biofilm state and become 
tolerant to antibiotics. The evolution of MRSA and the presence of newer, more 
aggressive, strains make the infections more dangerous and harder to treat. To date, 
there are no approved drugs targeting bacterial biofilms and only a very limited number 
of compounds can selectively eradicate them at low concentration.  
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This study highlights the use of AA and DHAA in the development of new anti-biofilm 
agents following the footsteps of Manner et al. (2015). In this work, 24 resin acid 
derivatives were successfully synthesized. The selected synthetic routes proved to be 
successful, except for the chlorination ones. The synthesized compounds will be tested 
for their biologically activity and selectivity compared to conventional antibiotics. The 
most potent compounds can be further tested for in vivo efficacy. Even if the 
synthesized compounds would not show clinical significance, they can still act as 
intermediates and be useful tools for future biofilm research. 
 
7 EXPERIMENTAL SECTION 
 
7.1 Reagents and equipment 
 
Reagents used for syntheses were utilized without further purification. Characterization 
of the compounds was done using 1H NMR and UPLC-HRMS. 1H NMR and 13C NMR 
were recorded on a Varian Mercury Plus 300 spectrometer. CDCl3 was used as a 
solvent and tetramethylsilane (TMS) as the internal standard. Chemical shifts and 
coupling constants (J) are reported in Hertz (Hz) and parts per million (δ), respectively. 
Multiplicities are reported using the following symbols: s (singlet), d (doublet), t 
(triplet), q (quartet), dd (doublet of doublets), dt (doublet of triplets), td (triplet of 
doublets), m (multiplet). 
 
For purification, automated flash column chromatography (FCC) on a Biotage High-
Performance Flash Chromatography Sp4-system (Uppsala, Sweden) equipped with a 
0.1 mm pathlength flow cell UV-detector/recorder module (fixed wavelength: 254 nm) 
was used. SNAP cartilage (25-50 g; flow rate 25 mL/min-30 mL/min) were used. 
 
A Vertex 70 (Bruker Optics Inc., MA, USA) FTIR instrument was used to acquire the 
IR spectra. The FTIR measurements were performed on a horizontal attenuated total 
reflectance (ATR) accessory (MIRacle, Pike Technology, Inc, WI, USA). The recording 
of the transmittance spectra was done at a 4 cm-1, resolution between 4000 and 600   
cm-1, using the OPUS 5.5 software (Bruker Optics Inc., MA, USA). UPLC-HRMS 
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analysis was done with UPLC system couple with TQD ESI mass spectrometer, both 
manufactured by Waters (Milford, USA). Analytical TLC was done on silica F254 
(Merck, Germany) sheets and the visualization with done under UV light (254 nm). 
 
Reagent Purity/concentration Supplier 
Abietic acid ~ 75% Sigma-Aldrich 
Acetic acid ≥ 99.8% Sigma-Aldrich 
Acetic anhydride ≥ 98.0% Sigma-Aldrich 
Acetone Laboratory reagent 
grade 
VWR chemicals 
Acetonitrile ≥ 99.9% Sigma-Aldrich 
Acetyl chloride 98% Sigma-Aldrich 
Aluminium chloride 99.9% Sigma-Aldrich 
( ̶ )-2-Aminobutyric acid 
methyl ester hydrochloride 
> 99% Bachem 
t-Butyl acetoacetate 97% Sigma-Aldrich 
t-Butyl alcohol ≥ 99.7% Sigma-Aldrich 
18-Crown-6 ≥ 99.0% Sigma-Aldrich 
Chloroform-d 99.8% Cambridge Isotope 
Laboratories  
Chloroform 99.0 - 99.4% Sigma-Aldrich 
3-Chloroperoxybenzoic acid ≤ 77%  Sigma-Aldrich 
Chromium(VI) oxide ≥ 98.0% Sigma-Aldrich 
Cyclohexane ≥ 99.7% Sigma-Aldrich 
ß-Cyclohexyl-L-alanine 
methyl ester hydrochloride 
95+% Ark Pharm, Inc. 
Dehydroabietic acid 90% Pfaltz & Bauer 
Dichloromethane ≥ 99.9% Sigma-Aldrich 
Diethyl ether ≥ 99.8% Sigma-Aldrich 
N,N-Diisopropylethylamine ≥ 98.0% Sigma-Aldrich 
Dimethylformamide 99.8% Sigma-Aldrich 
N-(3-Dimethylaminopropyl)- 
N'-ethylcarbodiimide 
hydrochloride ≥ 98.0% Sigma-Aldrich 
Ethanol 96% Altia Oyj 
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Ethyl acetate ≥ 99.5% Sigma-Aldrich 
Hexane ≥ 97.0% Sigma-Aldrich 
Heptane ≥ 99%  Sigma-Aldrich 
Hydrochloric acid ≥ 37%  Sigma-Aldrich 
Hydroxybenzotriazole ≥ 98.0% Sigma-Aldrich 
Hydroxylamine 
hydrochloride ≥ 99.0% 
Sigma-Aldrich 
Iodomethane ≥ 99.0% Sigma-Aldrich 
L-Leucine methyl ester 
hydrochloride 
98% Sigma-Aldrich 
Magnesium sulfate ≥ 99.5% Sigma-Aldrich 
Methanol ≥ 99.9% Sigma-Aldrich 
Palladium on activated 
charcoal 
10% Pd Sigma-Aldrich 
Peracetic acid 36-40 wt.% in acetic 
acid  
Sigma-Aldrich 
Potassium carbonate 99.5-100.5% Merck 
Potassium hydroxide Na < 0.002% Sigma-Aldrich 
Pyridine 99.8% Sigma-Aldrich 
Sodium bicarbonate 100.0% BDH Chemicals 
Sodium hydroxide ≥ 99% Merck 
Sodium sulfate ≥ 99.0% Sigma-Aldrich 
Sulfuric acid 95.0 - 97.0% Sigma-Aldrich 
Tetrahydrofuran ≥ 99.9% Sigma-Aldrich 
p-Toluenesulfonic acid 
monohydrate 
≥ 98.5% Sigma-Aldrich 
4-Toluenesulfonyl chloride 99+% Acros Organics 
Trifluoroacetic acid 99% Sigma-Aldrich 
D-Tryptophan methyl ester 
hydrochloride 
≥ 95% Chem-Impex International, 
Inc. 
 
Table 3.  List of reagents. 
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7.2 Syntheses 
 
Methyl N-(abiet-8,11,13-trien-18-oyl) cyclohexyl-L-alaninate (80). 3 (2.00 g, 6.65 
mmol) was dissolved in DMF (15 mL). EDC hydrochloride (1.90 g, 9.98 mmol, 1.5 
equiv.) and HOBt monohydrate (1.30 g, 9.98 mmol, 1.5 equiv.) were added and the 
mixture was stirred for 1 hour. β-cyclohexyl-L-alanine methyl ester hydrochloride (2.10 
g, 9.98 mmol, 1.5 equiv.) and DIPEA (3.4 mL, 19.95 mmol, 3 equiv.) were added and 
the mixture was stirred at rt for another hour. The mixture was then diluted with water 
(50 mL) and extracted with diethyl ether (3 × 100 mL). The resulting organic phase was 
washed with a 1 M aqueous solution of HCl (50 mL), a saturated solution of NaHCO3 
(50 mL), water (50 mL) and brine (50 mL) then dried with anhydrous Na2SO4. The 
mixture was filtered, evaporated under reduced pressure and purified with automated 
column chromatography (SNAP 50 G, n-hexane / EtOAC, 4/1). After evaporation of 
solvents, a white solid powder was obtained (2.38 g, 77%). 
 
1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.1 Hz, 1H, Ar-H), 7.0 (dd, J = 8.1, 1.8 Hz, 
1H, Ar-H), 6.89 (s, 1H, Ar-H), 6.07 (d, J = 8.1 Hz, 1H, NH), 4.67 (m, 1H), 3.72 (s, 3H, 
OCH3), 2.88 (m, 3H), 2.32 (d, J = 12.9 Hz, 1H), 2.09 (dd, J = 12.4, 2.1 Hz, 1H), 1.30 (s, 
3H), 1.24 (s, 3H), 1.23 (s, 3H), 1.21 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 178.1 
(C=O), 173.9 (C=O), 146.9 (Ar-C), 145.7 (Ar-C), 134.7 (Ar-C), 126.9 (Ar-C), 124.1 
(Ar-C), 123.9 (Ar-C), 52.1, 50.1, 47.3 (OCH3), 45.8, 40.0, 38.0, 37. 3, 37.2, 34.4, 33.6, 
33.4, 32.4, 30.0, 26.4, 26.3, 26.1, 25.2, 24.0, 23.9, 21.1, 18.7, 16.4. IR (ATR) 3359 (N-
H), 2923 (C-H), 1743 (C=O), 1637 (C=O), 1518 (Ar-C=C), 1443, 1202, 822 cm-1. 
 
N-(Abiet-8,11,13-trien-18-oyl) cyclohexyl-L-alanine (81). Compound 80 (0.10 g, 0.21 
mmol) was dissolved in THF:MeOH 1:1 (3 mL) under magnetic stirring at 0 °C. A 4 M 
aqueous solution of NaOH (1.8 mL) was added dropwise. The mixture was left to 
agitate at rt for 1 hour, after which the reaction was quenched by the addition of a 4 M 
aqueous solution of HCl dropwise until the pH reached 6-7. The mixture was 
concentrated under reduced pressure, diluted with water (20 ml) and extracted with 
diethyl ether (3 × 50 mL). The resulting organic phase was washed with a 1 M aqueous 
solution of HCl (30 mL), water (30 mL) and brine (30 mL), dried with Na2SO4, filtered, 
and evaporated to dryness to yield 81 as a white solid powder (94 mg, 98%). 
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1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.4 Hz, 1H, Ar-H), 7.00 (dd, J = 8.1, 2.1 Hz, 
1H, Ar-H), 6.89 (s, 1H, Ar-H), 6.11 (d, J = 6 Hz, 1H, NH), 4.63 (m, 1H), 2.83 (m, 3H), 
2.33 (d, J = 12.3 Hz, 1H), 2.10 (dd, J = 12.3, 2.1 Hz, 1H), 1.66 (m, 16 H), 1.44 (s, 2H), 
1.31 (s, 3H), 1.24 (s, 6H), 1.21 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 179.2 (C=O), 
176.7 (C=O), 146.8 (Ar-C), 145.7 (Ar-C), 134.6 (Ar-C), 126.9 (Ar-C), 124.0 (Ar-C), 
50.5, 47.3, 45.7, 41.5, 39.3, 38.0, 37.9, 37.2, 34.4, 33.6, 33.5, 32.3, 29.9, 26.3, 26.2, 
26.0, 25.2, 24.1, 24.0, 21.1, 18.7, 16.4. IR (ATR) 3336 (N-H), 2923 (C-H), 1731 (C=O), 
1626 (C=O), 1524 (Ar-C=C), 1227, 821 cm-1. 
 
Methyl N-(abiet-8,11,13-trien-18-oyl) D-tryptophanate (82). Following the procedure 
for compound 80, compound 82 was prepared from 3 (0.500 g, 1.66 mmol), HOBt 
monohydrate (337 mg, 2.49 mmol, 1.5 equiv.), EDC hydrochloride (478 mg, 2.49 
mmol, 1.5 equiv.), D-tryptophan methyl ester hydrochloride (634 mg, 2.49 mmol, 1.5 
equiv.) and DIPEA (0.84 mL, 4.98 mmol, 3 equiv.) in DMF (5 mL). After the 
purification with automated column chromatography (SNAP 50 G, n-hexane / EtOAC, 
3/1), compound 82 was obtained as a white solid powder (433 mg, 52%). 
 
1H NMR (300 MHz, CDCl3) 8.14 (s, 1H, NH), 7.54 (d, J = 9 Hz, 1H, Ar-H), 7.34 (m, 
1H, Ar-H), 7.19 (m, 1H, Ar-H), 7.13 (d, J = 6 Hz, 1H, Ar-H), 7.06 (m, 1H, Ar-H), 6.98 
(dd, J = 9, 3 Hz, 2H, Ar-H), 6.82 (d, J = 3 Hz, 1H, Ar-H), 6.28 ( d, J = 9 Hz, 1H, NH), 
4.94 (m, 1H), 3.71 (s, 3H, OCH3), 3.31 (d, J = 6 Hz, 2H), 2.82 (m, 3H), 2.27 (d, J = 15 
Hz, 1H), 2.04 (dd, J = 12, 3 Hz, 1H), 1.60 (m, 9H), 1.23 (s, 2H), 2.30 (s, 2H), 1.29 (d, J 
= 9 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 178.2 (C=O), 172.8 (C=O), 146.9 (Ar-C), 
145.6 (Ar-C), 136.1 (Ar-C), 134.7 (Ar-C), 127.6 (Ar-C), 126.8 (Ar-C), 124.0 (Ar-C), 
123.8 (Ar-C), 122.5 (Ar-C), 122.3 (Ar-C), 119.7 (Ar-C), 118.6 (Ar-C), 111.2 (Ar-C), 
110.3 (Ar-C), 53.1, 52.2, 47.2 (OCH3), 45.5, 37.9, 37.0, 33.4, 29.8, 27.5, 25.1, 24.0, 
24.0, 20.9, 18.7, 16.2. IR (ATR) 3296 (N-H), 1738 (C-H), 1640 (C=O), 1500 (Ar-C=C), 
1207, 741 cm-1. 
 
N-(Abiet-8,11,13-trien-18-oyl) D-tryptophan (83). Following the procedure for 
compound 81, 83 was prepared from 82 (0.20 g, 0.39 mmol) using THF:MeOH 1:1 (4.0 
mL) and a 4 M aqueous solution of NaOH (3.4 mL). The reaction gave compound 83 as 
a white solid (150 mg, 79%). 
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1H NMR (300 MHz, CDCl3) δ 8.17 (s, 1H, NH), 7.56 (d, J = 7.8 Hz, 1H, Ar-H), 7.27 
(m, 2H, Ar-H), 7.06 (m, 5H, Ar-H), 6.79 (s,1H, Ar-H), 6.29 (d, J = 6.9, 1H, NH), 4.86 
(q, J = 6.3 Hz, 1H), 3.36 (m, 2H), 2.68 (m, 3H), 2.24 (d, J = 12.9 Hz, 1H), 2.04 (s, 1H), 
1.92 (d, J = 12.3 Hz, 1H), 1.50 (m, 7H), 1.22 (d, J = 6.9 Hz, 6 H), 1.13 (s, 3H), 1.06 (s, 
3H).13C NMR (75 MHz, CDCl3) δ 180.0 (C=O), 174.89 (C=O), 146.7 (Ar-C), 145.6 
(Ar-C), 136.1 (Ar-C), 134.6 (Ar-C), 127.5 (Ar-C), 126.8 (Ar-C), 124.0 (Ar-C), 123.8 
(Ar-C), 123.0 (Ar-C), 122.4 (Ar-C), 119.9 (Ar-C), 118.3 (Ar-C), 111.4 (Ar-C), 109.6 
(Ar-C), 53.6, 47.3, 45.6, 37.8, 36.9, 36.8, 33.4, 29.6, 26.5, 25.1, 24.0, 24.0, 20.8, 18.5, 
16.1. IR (ATR) 3413 (N-H), 2928 (O-H), 1721 (C=O), 1619 (C=O), 1505 (Ar-C=C), 
741 cm-1. 
 
Methyl N-(abiet-8,11,13-trien-18-oyl) L-leucinate (84). Following the procedure for 
compound 80, 84 was prepared from DHAA (0.500 g, 1.66 mmol), HOBt monohydrate 
(337 mg, 2.49 mmol, 1.5 equiv.), EDC hydrochloride (478 mg, 2.49 mmol, 1.5 equiv.), 
L-leucine methyl ester hydrochloride (452 mg, 1.24 mmol, 1.5 equiv.), and DIPEA 
(0.84 mL, 4.98 mmol, 3 equiv.) in DMF (5 mL). The compound was purified by 
automated column chromatography (SNAP 50 G, n-hexane / EtOAC, 4/1) to give 84 as 
a white solid (380 mg, 54%). 
 
1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.1 Hz, 1H, Ar-H), 7.0 (dd, J = 8.1, 2.1 Hz, 
1H, Ar-H), 6.89 (s, 1H, Ar-H), 6.07 (d, J = 9 Hz, 1H, NH), 4.63(m, 1H), 3.73 (s, 3H, 
OCH3), 2.87 (m, 3H), 2.33 (d, J = 13.2 Hz, 1H), 2.08 (dd, J = 12.3, 2.1 Hz, 1H), 1.77 
(m, 11H), 1.30 (s, 3H), 1.22 (m, 9H), 0.95 (d, J = 5.1 Hz, 6H). 13C NMR (75 MHz, 
CDCl3) δ 178.1 (C=O), 173.8 (C=O), 146.9 (Ar-C), 145.7 (Ar-C), 134.7 (Ar-C), 126.9 
(Ar-C), 124.0 (Ar-C), 123.9 (Ar-C), 52.1, 50.9, 47.3 (OCH3), 45.8, 41.5, 38.1, 37.4, 
37.2, 33.4, 29.9, 25.2, 25.1, 24.0, 23.9, 22.8, 21.9, 21.1, 18.7, 16.4. IR (ATR) 3353 (N-
H), 2955 (C-H), 1744 (C=O), 1637 (C=O), 1516 (Ar-C=C), 1202, 823 cm-1. 
 
N-(Abiet-8,11,13-trien-18-oyl) L-leucine (85). Following the procedure for compound 
81, compound 85 was prepared from compound 80 (297 mg, 0.69 mmol) using 
THF:MeOH 1:1 (7.3 mL) and a 4 M aqueous solution of NaOH (6 mL). Compound 85 
was obtained as a white solid (124 mg, 43%). 
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1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.1 Hz, 1H, Ar-H), 7.00 (dd, J = 8.1, 2.1 Hz, 
1H, Ar-H), 6.89 (m, 1H, Ar-H), 6.06 (d, J = 7.8 Hz, 1H, NH), 4.63 (m, 1H), 2.85 (m, 
3H), 2.33 (d, J = 13.2 Hz, 1H), 2.09 (dd, J = 12.3, 2.1 Hz, 1H), 1.78 (m, 12H), 1.31 (s, 
3H), 1.23 (d, J = 6.9 Hz, 9H), 0.97 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 179.3 (C=O), 
176.1 (C=O), 146.8 (Ar-C), 145.8 (Ar-C), 134.6 (Ar-C), 127.0 (Ar-C), 124.0 (Ar-C), 
123.9 (Ar-C), 51.3, 47.4, 45.8, 40.8, 38.1, 37.4, 37.2, 33.5, 29.9, 25.2, 25.1, 24.0, 23.9, 
22.9, 21.8, 21.2, 18.7, 16.4. IR (ATR) 3668 (N-H), 2957 (C-H), 1721 (C=O), 1631 
(C=O), 1517 (Ar-C=C), 1195, 821 cm-1. 
 
Methyl N-(abiet-8,11,13-trien-18-oyl) L-ethylglycinate (86). Following the procedure 
for compound 80, compound 86 was prepared from 3 (0.500 g, 1.66 mmol), HOBt 
monohydrate (337 mg, 2.49 mmol, 1.5 equiv.), EDC hydrochloride (478 mg, 2.49 
mmol, 1.5 equiv.), (-)-2-aminobutyric acid methyl ester hydrochloride (384 mg, 2.49 
mmol, 1.5 equiv.), and DIPEA (0.84 mL, 4.98 mmol, 3 equiv.) in DMF (5 mL). The 
compound was purified by automated column chromatography (SNAP 50 G, n-hexane / 
EtOAC, 4/1) to give 86 as a white solid (371 mg, 56%). 
 
1H NMR (300 MHz, CDCl3) δ 7.15 (d, J = 8.1 Hz, 1H, Ar-H), 6.98 (dd, J = 8.1, 2.1 Hz, 
1H, Ar-H), 6.87 (s, 1H, Ar-H), 6.23 (d, J = 7.5 Hz, 1H, NH), 4.57 (m, 1H), 3.73 (s, 3H, 
OCH3), 2.86 (m, 3H), 2.30 (d, J = 12.9 Hz, 1H), 2.09 (dd, J = 12.3, 2.1 Hz, 1H), 1.73 
(m, 10 H), 1.30 (s, 3H), 1.21 (m, 9H), 0.91 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 178.0 (C=O), 173.1 (C=O), 146.9 (Ar-C), 145.7 (Ar-C), 134.6 (Ar-C), 126.9 
(Ar-C), 124.0 (Ar-C), 123.8 (Ar-C), 53.3, 52.1, 47.3 (OCH3), 45.7, 38.0, 37.5, 37.1, 
33.4, 29.9, 25.5, 25.2, 23.9, 23.9, 21.1, 18.7, 16.3, 9.6. IR (ATR) 3347 (N-H), 2956 (C-
H), 1742 (C=O), 1638 (C=O), 1506 (Ar-C=C), 1204, 822 cm-1. 
 
N-(Abiet-8,11,13-trien-18-oyl) L-ethylglycine (87). Following the procedure for 
compound 81, 87 was prepared from 3 (0.20 g, 0.50 mmol) using THF:MeOH 1:1 (4.9 
mL) and a 4 M aqueous solution of NaOH (4 mL). The reaction yielded compound 87 
as a white solid powder (151 mg, 78%). 
 
1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 8.1 Hz, 1H, Ar-H), 7.00 (dd, J = 8.1, 2.1 Hz, 
1H, Ar-H), 6.88 (s, 1H, Ar-H), 6.32 (d, J = 7.2 Hz, 1H, NH), 4.55 (dd, J = 12.3, 6.9 Hz, 
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1H), 2.85 (m, 3H), 2.33 (d, J = 12.6 Hz, 1H), 2.11 (dd, J = 12.6, 2.1 Hz, 1H), 1.75 (m, 
11H), 1.31 (s, 3H), 1.24 (s, 3H), 1.23 (s, 3H), 1.21 (s, 3H), 0.96 (t, J =7.5 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 179.1 (C=O), 176.2 (C=O), 146.8 (Ar-C), 145.8 (Ar-C), 
134.6 (Ar-C), 126.9 (Ar-C), 124.1 (Ar-C), 123.9 (Ar-C), 53.7, 47.4, 45.6, 38.0, 37.3, 
37.1, 33.4, 29.9, 25.3, 25.1, 24.0, 23.9, 21.2, 18.7, 16.4, 9.7. IR (ATR) 3328 (N-H), 
2957 (O-H), 1714 (C=O), 1630 (C=O), 1520 (Ar-C=C), 1296, 820 cm-1. 
 
Methyl (abiet-8,11,13-trien-18-oyl) carboxylate (88). 3 (0.500 g, 1.66 mmol) was 
dissolved in DMF (4 mL), at rt. K2CO3 (573 mg, 4.15 mmol, 2.5 equiv.) and MeI (0.20 
ml, 3.32 mmol, 2 equiv.) were added and the mixture was stirred for 3 hours 15 
minutes. The mixture was then diluted with a 1 M aqueous solution of HCl (50 mL) and 
extracted with diethyl ether (3 × 75 mL). The resulting organic phase was washed with 
1 M HCl (50 mL), a saturated solution of NaHCO3 (50 mL), water (50 mL) and brine 
(50 mL), then dried with anhydrous Na2SO4. The mixture was filtered, and evaporated 
under reduced pressure to yield compound 88 as a yellow oil (461 mg, 88%). 
 
 1H NMR (300 MHz, CDCl3) δ 7.16 (d, J = 8.1 Hz, 1H, Ar-H), 7.00(d, J = 8.1 Hz, 1H, 
Ar-H), 6.88 (s, 1H, Ar-H), 3.66 (s, 3H, OCH3), 2.86 (m, 2H), 2.27 (m, 2H), 1.71 (m, 
11H), 1.29 (s, 3H), 1.23 (d, J = 7.2 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 179.0 
(C=O), 146.9 (Ar-C), 145.7 (Ar-C), 134.7 (Ar-C), 126.8 (Ar-C), 124.1 (Ar-C), 123.9 
(Ar-C), 51.8 (OCH3), 47.6, 44.9, 38.0, 36.9, 36.6, 33.4, 30.0, 25.0, 23.9, 21.7, 18.6, 
16.5. IR (ATR) 2929 (C-H), 1722 (C=O), 1246, 1176, 1128, 825 cm-1. 
 
Methyl (7-oxoabiet-8,11,13-trien-18-oyl) carboxylate (89). To a solution of 
chromium (VI) oxide (2.10 g, 21.0 mmol, 1.1 equiv.) in glacial acetic acid (28 mL) and 
ethyl acetate (60 mL) was added dropwise a suspension of compound 88 (6.02 g, 19.10 
mmol) in glacial acetic over a period of 10 minutes. The reaction mixture was warmed 
to 50 °C. After 4 hours, more chromium (VI) oxide (2.10 g, 21.01 mmol, 1.1 equiv.) 
was added and after another hour the reaction was completed. After the reaction cooled 
down, it was diluted with water (150 mL) and dichloromethane (200 mL). The aqueous 
phase was further extracted with dichloromethane (2 × 100 mL). The combined organic 
phases were washed with water (50 mL), a saturated aqueous solution of NaHCO3 (50 
mL), water (50 mL), and brine (50 mL), dried with Na2SO4, filtered and evaporated to 
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dryness. Purification by automated column chromatography (SNAP 50 G, cyclohexane / 
EtOAC, 1/2) yielded 89 as a colorless oil (2.85 g, 45%). 
 
1H NMR (300 MHz, CDCl3) δ 7.86 (s, 1H, Ar-H), 7.40 (d, J = 8.1 Hz, 1H, Ar-H), 7.29 
(d, J = 8.1 Hz, 1H, Ar-H), 3.65 (s, 3H, OCH3), 2.92 (m, 1H), 2.72 (m, 2H), 2.35 (m, 
2H), 1.69 (m, 5H), 1.43 (s, 3H), 1.34 ( s, 3H), 1.24 (d, J = 6.6 Hz, 6H). 13C NMR (75 
MHz, CDCl3) δ 198.5 (C=O), 177.8 (C=O), 153.0 (Ar-C), 146.9 (Ar-C), 132.5 (Ar-C), 
130.7 (Ar-C), 125.0 (Ar-C), 123.4 (Ar-C), 52.1 (OCH3), 46.7, 43.8, 37.8, 37.3, 37.1, 
36.5, 33.6, 26.9, 23.8, 23.7, 18.2, 16.4. IR (ATR) 2925 (C-H), 1726 (C=O), 1681 
(C=O), 1247, 1116, 834 cm-1. 
 
Methyl (7-hydroiminoabiet-8,11,13-trien-18-oyl) carboxylate (90). The methyl ester 
89 (2.71 g, 8.24 mmol) was dissolved in EtOH (18 mL), at rt. NH2OH·HCl (916 mg, 
13.20 mmol, 1.6 equiv.) and pyridine (0.9 mL) were added and the mixture was stirred 
at 100 °C for 2 hours and 30 minutes, after which the mixture was left to stir overnight 
at rt. The solvent was evaporated in vacuum and the residue was purified by automated 
column chromatography (SNAP 50 G, cyclohexane / EtOAC, 6/1) to yield 90 as a white 
solid (2.74 g, 97%). 
 
1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H, Ar-H), 7.71 (s, 1H, Ar-H), 7.21 (m, 1H, Ar-
H), 3.66 (s, 3H, OCH3), 2.90 (m, 1H), 2.67 (m, 2H), 2.32 (m, 2H), 1.67 (m, 5H), 1.38 
(s, 3H), 1.25 (d, J = 6.0 Hz, 6H), 1.12 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 178.2 
(C=O), 155.8 (CNOH), 148.7 (Ar-C), 146.6 (Ar-C), 128.8 (Ar-C), 128.0 (Ar-C), 122.9 
(Ar-C), 122.1 (Ar-C), 52.0, 46.6 (OCH3), 41.7, 37.2, 37.1, 36.6, 33.7, 26.9, 24.0, 23.8, 
23.6, 23.0, 18.2. IR (ATR) 3246, 2928, 1726, 1251, 963, 829 cm-1. 
 
Methyl abiet-8,11,13-trien-18-oate 4-tosyloxyimine (91). The methyl ester 90 (2.61 g, 
7.59 mmol) was dissolved in pyridine (7 mL), at rt. TsCl (2.17 mg, 11.4 mmol, 1.5 
equiv.) was added and the mixture was stirred overnight at rt. The solvent was 
evaporated in vacuo and the residue was purified by FCC (SNAP 50 G, n-heptane / 
EtOAC, 4/1). As the crude compound was a mixture of TsCl and compound 91, it was 
further washed with water (20 mL), a saturated aqueous solution of NaHCO3 (3 × 20 
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mL), and brine (30 mL), dried with Na2SO4, filtered and evaporated to dryness to yield 
91 as a white solid (1.42 g, 38%). 
 
1H NMR (300 MHz, CDCl3) δ 7.96 (d, J = 9 Hz, 2H, Ar-H), 7.59 (s, 1H, Ar-H), 7.35 (d, 
9 Hz, 2H, Ar-H), 7.24 (s, 1H, Ar-H), 7.18 (d, J = 9 Hz, 1H, Ar-H), 3.66 (s, 3H, OCH3), 
2.87 (m, 1H), 2.66 ( d, J = 9 Hz, 2H), 2.44 (s, 3H, CH3), 2.26 (t, J = 9 Hz, 2H), 1.64 (m, 
5H), 1.34 (s, 3H), 1.22 (d, J = 6 Hz, 6H, 2CH3), 1.04 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 177.8 (C=O), 162.6 (CNO), 150.0 (Ar-H), 146.6 (Ar-H), 144.9 (Ar-H), 132.9 
(Ar-H), 130.0 (Ar-H), 129.4 (Ar-H), 129.1 (Ar-H), 126.4 (Ar-H), 123.3 (Ar-H), 123.1 
(Ar-H), 52.2, 46.2 (OCH3), 41.4, 37.2, 36.9, 36.5, 33.5, 25.0, 23.8, 23.6, 23.0, 21.6, 
18.0, 16.5. IR (ATR) 2958 (C-H), 1721 (C=O), 1374, 1183, 814 cm-1. UPLC-HRMS 
m/z: calcd. for C28H35NO5S 498.2269 [M+H]+, found 498.2318. 
 
Methyl (7aR,8R,11aS)-3-isopropyl-8,11a-dimethyl-6-oxo-6,7,7a,8,9,10,11,11a-
octahydro-5H-dibenzo[b,d]azepine-8-carboxylate (92). A suspension of compound 
91 (1.31 g, 2.64 mmol) in TFA (7.8 mL) was stirred at rt for 1 hour, after which the 
reaction was completed. The solvent was evaporated in vacuo and the residue was 
purified by FCC (SNAP 50 G, n-heptane /EtOAC = 1:1) to give 92 (864 mg, 97%) as a 
colorless amorphous solid. 
 
1H NMR (300 MHz, CDCl3) δ 7.50 (s, 1H, NH), 7.31 (d, J = 6 Hz, 1H, Ar-H), 7.00 (dd, 
J = 6, 3 Hz, 1H, Ar-H), 6.70 (d, J = 3 Hz, 1H, Ar-H), 3.65 (s, 3H, OCH3), 2.87 (m, 1H), 
2.78 (dd, J = 6, 3 Hz, 1H), 2.54 (dd, J = 15, 9 Hz, 1H), 2.17 (m, 1H), 1.80 (m, 6H), 1.44 
(d, J = 12 Hz, 6H), 1.23 (d, J = 6 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 178.1 (C=O), 
175.2 (C=O), 148.0 (Ar-C), 139.7 (Ar-C), 135.6 (Ar-C), 126.5 (Ar-C), 122.98 (Ar-C), 
120.64 (Ar-C), 52.09, 49.76 (OCH3), 48.2, 40.6, 39.6, 36.6, 36.3, 33.2, 23.7, 22.1, 18.2, 
17.0 cm-1. IR (ATR) 3209 (N-H), 3111, 2953 (C-H), 1676 (C=O), 1390, 819. UPLC-
HRMS m/z: calcd. for C21H29NO3 344.2181 [M+H]+, found 344.2231. 
 
(7aR,8R,11aS)-3-isopropyl-8,11a-dimethyl-6-oxo-6,7,7a,8,9,10,11,11a-octahydro-
5H-dibenzo[b,d]azepine-8-carboxylic acid (93). Compound 92 (0.400 g, 1.16 mmol) 
was dissolved in MeOH (8 mL) at rt. KOH (654 mg, 11.6 mmol, 10 equiv.) and 18-
crown-6 (767 mg, 2.90 mmol, 2.5 equiv.) were added, and the resulting mixture was 
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stirred at 80 °C for 23 hours. After the mixture had cooled, the solvent was evaporated 
in vacuo. The residue was diluted with a 1 M aqueous solution of HCl (50 ml) and 
extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed 
with brine (30 mL), dried over Na2SO4, filtered and evaporated to dryness. The residue 
was purified by automated column chromatography (SNAP 25 G, n-heptane / 
EtOAC = 1:2) to yield 93 (451 mg, 59%) as a white solid. 
 
1H NMR (300 MHz, CDCl3) δ 8.76 (s, 1H, NH), 7.30 ( d, J = 6 Hz, 1H, Ar-H), 7.00 (d, 
J = 9 Hz, 1H, Ar-H), 6.75 (s, 1H, Ar-H), 2.83 (m, 2H), 2.65 (dd, J = 15, 9 Hz, 1H), 2.26 
(d, J = 15 Hz, 1H), 2.06 (d, J = 12 Hz, 1H), 1.84 (m, 5H), 1.43 (d, J = 6 Hz, 6H), 1.22 
(d, J = 6 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 182.4 (C=O), 177.4 (C=O), 148.0 (Ar-
C), 139.9 (Ar-C), 135.3 (Ar-C), 126.5 (Ar-C), 123.2 (Ar-C), 121.0 (Ar-C), 49.4, 48.2, 
40.5, 39.6, 36.4, 33.2, 23.7, 22.1, 20.8, 18.2, 16.9. IR (ATR) 2956 (C-H), 1692 (C=O), 
1635 (C=O), 1395, 730 cm-1. UPLC-HRMS m/z: calcd. for C20H27NO3 330.2024 
[M+H]+, found 330.2076. 
 
Methyl (S)-3-cyclohexyl-2-((7aR,8R,11aS)-3-isopropyl-8,11a-dimethyl-6-oxo-
6,7,7a,8,9,10,11,11a-octahydro-5H-dibenzo[b,d]azepine-8-carboxamido)propanoate 
(94). Compound 93 (340 mg, 1.03 mmol) was dissolved in DMF (3.4 mL), at rt. EDC 
hydrochloride (296 mg, 1.55 mmol, 1.5 equiv.) and HOBt monohydrate (208 mg, 1.55 
mmol, 1.5 equiv.) were added and the mixture was stirred for 1 hour. β-cyclohexyl-L-
alanine methyl ester hydrochloride (343 mg, 1.55 mmol, 1.5 equiv.) and DIPEA (0.60 
mL, 3.09 mmol, 3 equiv.) were added, and the resulting mixture was left to stir for 1 
hour 20 minutes. The mixture was then diluted with water (30 mL) and extracted with 
diethyl ether (3 × 50 mL). The resulting organic phase was washed with a 1 M aqueous 
solution of HCl (50 mL), a saturated solution of NaHCO3 (50 mL), water (50 mL), and 
brine (50 mL) and dried with anhydrous Na2SO4. The mixture was filtered, evaporated 
under reduced pressure and purified by automated column chromatography (SNAP 25 
G, n-hexane / EtOAC, 1/1). After evaporation of solvents, a white solid was obtained 
(289 mg, 57%). 
 
1H NMR (300 MHz, CDCl3) δ 7.37 (s, 1H, NH), 7.30 (d, J = 9 Hz, 1H, Ar-H), 7.00 (d, J 
= 9 Hz, 1H, Ar-H), 6.72 (s, 1H, Ar-H), 6.23 (d, J = 9 Hz, 1H, NH), 4.61 (m, 1H, CH), 
50 
 
3.71 (s, 3H, OCH3), 2.83 (m, 2H), 2.59 (m, 1H), 2.06 (d, J = 12 Hz, 1H), 1.76 (m, 14H), 
1.48 (s, 6H), 1.14 (m, 11H). 13C NMR (75 MHz, CDCl3) δ 177.20 (C=O), 175.1 (C=O), 
173.7 (C=O), 148.0 (Ar-C), 141.1 (Ar-C), 136.0 (Ar-C), 125.4 (Ar-C), 123.4 (Ar-C), 
121.0 (Ar-C), 52.2, 50.4, 49.8 (OCH3), 49.6, 40.1, 39.8, 38.7, 36.5, 36.0, 34.3, 33.4, 
33.3, 32.5, 31.9, 26.3, 26.1, 26.0, 23.8, 21.6, 18.2, 16.8. IR (ATR) 2924 (C-H), 2854, 
1737 (C=O), 1662 (C=O), 1206, 824 cm-1. UPLC-HRMS m/z: calcd. for C30H44 N2O4 
497.3335 [M+H]+, found 497.3379. 
 
(S)-3-cyclohexyl-2-((7aR,8R,11aS)-3-isopropyl-8,11a-dimethyl-6-oxo- 
6,7,7a,8,9,10,11,11a-octahydro-5H-dibenzo[b,d]azepine-8-carboxamido)propanoic 
acid (95). Compound 94 (0.20 g, 0.39 mmol) was dissolved in THF:MeOH 1:1 (4.8 
mL) under magnetic stirring at 0 °C. A 4 M aqueous solution of NaOH (4.4 mL) was 
added dropwise. The mixture was left to agitate at rt for 1 hour, after which the reaction 
was quenched by the addition of a 4 M aqueous solution of HCl dropwise until the pH 
reached 6-7. The mixture was concentrated under reduced pressure, diluted with water 
(20 ml) and extracted with diethyl ether (3 × 50 mL). The resulting organic phases were 
combined and washed with a 1 M aqueous solution of HCl (30 mL), water (30 mL), 
brine (30 mL) and dried with Na2SO4. The mixture was filtered, evaporated under 
reduced pressure and purified by automated column chromatography (SNAP 25 G, n-
heptane / EtOAC, 1/1). After evaporation of solvents, a white solid was obtained (137 
mg, 73%). 
 
1H NMR (300 MHz, CDCl3) δ 8.70 (s, 1H, NH), 7.30 (d, J = 8.4 Hz, 1H, Ar-H), 7.01 
(d, J = 7.8 Hz, 1H, Ar-H), 6.75 (s, 1H, Ar-H), 6.38 (d, J = 7.8 Hz, 1H, NH), 4.60 (q, J = 
7.2 Hz, 1H), 2.81 (m, 2H), 2.57 (m, 1H), 2.09 (s, 3H), 1.72 (m, 13 H), 1.46 (d, J = 3.3 
Hz, 6H), 1.22 (d, J = 6.9 Hz, 6H), 0.94 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 177.5 
(C=O), 177.0 (C=O), 176.4 (C=O), 148.0 (Ar-C), 140.6 (Ar-C), 135.5 (Ar-C), 125.8 
(Ar-C), 123.5 (Ar-C), 121.1 (Ar-C), 50.7, 49.7, 49.6, 40.2, 39.8, 39.0, 36.3, 35.5, 34.3, 
33.4, 33.2, 32.5, 26.4, 26.1, 26.0, 23.7, 21.9, 20.7, 18.3. IR (ATR) 2924 (C-H), 1709 
(C=O), 1637 (C=O), 1395, 1215, 825 cm-1. UPLC-HRMS m/z: calcd. for C29H42 N2O4 
483.3178 [M+H]+, found 483.3223. 
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Methyl (12-acetylabiet-8,11,13-trien-18-oyl) carboxylate (96). Compound 88 (2.00 g, 
6.36 mmol) was dissolved in CH2Cl2 (31 mL), then AcCl (1.16 ml, 13.99 mmol, 2.2 
equiv.) was added to the mixture. The reaction was left stirring at 0 °C for 5 minutes. 
After which AlCl3 (1.70 g, 12.7 mmol, 2 equiv.) was added and the mixture was left to 
agitate for 45 minutes at 0 °C. Then the reaction stirred at rt for another hour, after 
which the reaction was completed. The mixture was concentrated under reduced 
pressure, diluted with a saturated aqueous solution of NaHCO3 (30 ml) and extracted 
with diethyl ether (3 × 50 mL). The resulting organic phase was washed with a saturated 
aqueous solution of NaHCO3 (2 × 50 mL) and brine (50 mL), dried with Na2SO4, 
filtered and evaporated to dryness to yield 96 as a green solid powder (2.02 mg, 89%). 
 
1H NMR (300 MHz, CDCl3) δ 7.39 (s, 1H, Ar-H), 7.03 (s, 1H, Ar-H), 3.66 (s, 3H, 
OCH3), 3.46 (m, 1H), 2.90 (q, J = 4.5 Hz, 2H), 2.54 (s, 3H, COCH3), 2.26 (m, 2H), 1.64 
(m, 7H), 1.27 (s, 3H), 1.20 (d, J = 3.6 Hz, 6H), 1.17 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 203.4 (C=O), 178.9 (C=O), 146.5 (Ar-C), 144.9 (Ar-C), 138.7 (Ar-C), 136.3 
(Ar-C), 127.0 (Ar-C), 124.3 (Ar-C), 52.0 (OCH3), 47.5 (CH), 44.7 (C), 37.8, 36.9, 36.6, 
30.5, 29.9, 28.7, 25.1, 24.3, 24.0, 21.4, 18.4, 16.5 cm-1. IR (ATR) 2926 (C-H), 1725 
(C=O), 1682 (C=O), 1248, 882. UPLC-HRMS m/z: calcd. for C23H32O3 357.2385 
[M+H]+, found 357.2438. 
 
Methyl (12-acetoxylabiet-8,11,13-trien-18-oyl) carboxylate (97). Compound 96 (1.88 
g, 5.27 mmol) was dissolved in CH2Cl2 (7.4 mL). A solution of peracetic acid (36 - 
40%, 12.3 mL, 199 mmol, 37.7 equiv.) in AcOH was added to the mixture, and the 
reaction mixture was left to stir at rt for 96 hours, after which the reaction was 
completed. The reaction was quenched by the addition of water (70 mL) and extracted 
with diethyl ether (4 × 70 mL). The resulting organic phases were combined and 
washed with a saturated aqueous solution of NaHCO3 (2 × 50 mL) and brine (50 mL) 
then dried with Na2SO4. The mixture was filtered, evaporated under reduced pressure 
and purified by silica gel column chromatography (SNAP 50 G, n-heptane / EtOAC, 
3/1). After evaporation of solvents, yellow oil was obtained (1.73 g, 88%). 
 
1H NMR (300 MHz, CDCl3) δ 6.93 (s, 1H, Ar-H), 6.82 (s, 1H. Ar-H), 3.66 (s, 3H, 
OCH3), 2.90 (m, 3H), 2.30 (s, 3H, OCOCH3), 2.21 (m, 2H), 1.76 (m, 9H), 1.53 (s, 1H), 
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1.27 (s, 3H), 1.19 (d, J = 8.4, 6H). 13C NMR (75 MHz, CDCl3) δ 179.0 (C=O), 170.0 
(C=O), 148.1 (Ar-C), 146.1 (Ar-C), 136.9 (Ar-C), 132.9 (Ar-C), 127.0 (Ar-C), 117.8 
(Ar-C), 52.0 (OCH3), 47.6, 44.4, 37.8, 37.0, 36.5, 29.5, 27.1, 25.0, 23.1, 22.9, 21.6, 
21.0, 18.4, 16.4 cm-1. IR (ATR) 2929 (C-H), 1760 (C=O), 1725 (C=O), 1207, 912. 
UPLC-HRMS m/z: calcd. for C23H32O4 373.2334 [M+H]+, found 373.2383. 
 
Methyl (12-hydroxiabiet-8,11,13-trien-18-oyl) carboxylate (98). Compound 97 
(0.430 g, 1.16 mmol) was dissolved in MeOH (6 mL). A 1 M aqueous solution of 
NaOH (1 mL) was added under magnetic stirring and the mixture was left to agitate at 
rt. After 1 hour 30 minutes, more 1 M NaOH (1 mL) was added, and after 30 minutes, 
the reaction was completed. The reaction was stopped by the addition of a 1 M aqueous 
solution of HCl dropwise until the pH reached 6-7. The mixture was concentrated under 
reduced pressure and extracted with diethyl ether (3 × 50 mL). The resulting organic 
phase was washed with brine (30 mL), dried with Na2SO4, filtered and evaporated to 
dryness. The residue was purified by silica gel column chromatography (SNAP 50 G, n-
hexane / EtOAC, 4/1) to give compound 98 as a yellow solid (244 mg, 64%).  
 
1H NMR (300 MHz, CDCl3) δ 6.82 (s, 1H, Ar-H), 6.62 (s, 1H, Ar-H), 3.66 (s, 3H, 
OCH3), 3.11 (m, 1H), 2.81 (m, 2H), 2.20 (m, 2H), 1.85 (m, 7H), 1.23 (m, 12H). 13C 
NMR (75 MHz, CDCl3) δ 179.1 (C=O), 150.8 (Ar-C), 147.9 (Ar-C), 131.7 (Ar-C), 
127.0 (Ar-C), 126.7 (Ar-C), 110.8 (Ar-C), 51.9 (OCH3), 47.7 (CH), 44.8, 38.0, 36.9, 
36.6, 29.2, 26.8, 24.9, 22.7, 22.5, 21.8, 18.6, 16.5 cm-1. IR (ATR) 3437 (O-H), 2948 (C-
H), 1694 (C=O), 1254, 859. UPLC-HRMS m/z: calcd. for C21H30 NO3 330.2024 
[M+H]+, found 330.2076. 
 
Methyl [12-acetyl-N-(abiet-8,11,13-trien-18-oyl)] cyclohexyl-L-alaninate (99). 
Compound 80 (2.24 g, 4.78 mmol) was dissolved in CH2Cl2 (34.6 mL), then AcCl (1.3 
ml, 18.28 mmol, 3.8 equiv.) was added to the mixture. The reaction mixture was left to 
stir at 0 °C for 5 minutes, after which AlCl3 (1.28 g, 9.55 mmol, 2 equiv.) was added 
and the mixture was left to agitate for 45 minutes at 0 °C. Afterwards, the reaction was 
left to stir at rt for 24 h. AcCl (0.65 ml, 9.20 mmol, 1.9 equiv.), AlCl3 (0.64 g, 4.77 
mmol, 1 equiv.) and CH2Cl2 (17 mL) were added and the mixture was stirred for 5 hours 
30 minutes, after which the reaction was heated at 35 °C for 1 hour, then stopped, 
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concentrated under reduced pressure, diluted with a saturated aqueous solution of 
NaHCO3 (30 ml) and extracted with diethyl ether (4 × 50 mL). The resulting organic 
phase was washed with a saturated aqueous solution of NaHCO3 (70 mL) and brine (70 
mL), dried with Na2SO4, filtered and evaporated to dryness. The residue was purified by 
automated column chromatography (SNAP 50 G, n-heptane / EtOAC, 3.5/1). After 
evaporation of solvents, yellow solid was obtained (1.67 g, 69%). 
 
1H NMR (300 MHz, CDCl3) δ 7.38 (s, 1H, Ar-H), 7.03 (s, 1H, Ar-H), 6.08 (d, J = 8.1 
Hz, 1H, NH), 4.68 (m, 1H), 3.72 (s, 3H, OCH3), 3.46 (m, 1H), 2.91 (m, 2H), 2.54 (s, 
3H, COCH3), 2.32 (d, J = 11.4 Hz, 1H), 2.11 (m, 1H), 1.67 (m, 17 H), 1.31 (s, 3H), 
1.236 (s, 3H), 1.19 (dd, J = 12, 6.9 Hz, 8H). 13C NMR (75 MHz, CDCl3) δ 203.2 
(C=O), 177.9 (C=O), 173.9 (C=O), 146.6 (Ar-C), 144.9 (Ar-C), 138.7 (Ar-C), 136.4 
(Ar-C), 127.0 (Ar-C), 124.2 (Ar-C), 52.2, 50.2, 47.2 (OCH3), 45.5, 40.1, 38.0, 37.1, 
34.5, 33.6, 32.4, 31.9, 30.5, 29.9, 28.7, 26.3, 26.1, 25.2, 24.2, 24.0, 22.7, 20.9, 18.6, 
16.4 cm-1. IR (ATR) 3360 (N-H), 2924 (C-H), 2363, 1743 (C=O), 1642 (C=O), 1518 
(Ar-C=C), 1261, 1202, 887. UPLC-HRMS m/z: calcd. for C32H47NO4 510.3539 
[M+H]+, found 510.3583. 
 
Methyl [12-acetoxy-N-(abiet-8,11,13-trien-18-oyl)] cyclohexyl-L-alaninate (100). 
Compound 99 (1.59 g, 3.12 mmol) was dissolved in CH2Cl2 (6.3 mL). A solution of 
peracetic acid (36 - 40%, 10.4 mL, 168.0 mmol, 54 equiv.) in AcOH was added to the 
mixture, and the reaction mixture was left to stir at rt for 96 hours, after which the 
reaction was completed. The reaction was quenched by the addition of water (100 mL) 
and extracted with diethyl ether (4 × 50 mL). The resulting organic phases were 
combined and washed with a saturated aqueous solution of NaHCO3 (3 × 50 mL) and 
brine (70 mL) then dried with Na2SO4. The mixture was filtered, evaporated under 
reduced pressure and purified by automated column chromatography (SNAP 50 G, n-
heptane / EtOAC, 3/1). After evaporation of solvents, yellow solid was obtained (1.40 
g, 85%). 
 
1H NMR (300 MHz, CDCl3) δ 6.94 (s, 1H, Ar-H), 6.82 (s, 1H, Ar-H), 6.05 (d, J = 9 Hz, 
1H, NH), 4.67 (m, 1H), 3.71 (s, 3H, OCH3), 2.92 (m, 3H), 2.29 (s, 3H, OCOCH3), 2.21 
(d, J = 12 Hz, 1H), 2.08 (d, J = 15 Hz, 1H), 1.69 (m, 15H), 1.28 (d, J = 3 Hz, 3 H), 1.23 
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(s, 3H), 1.17 (t, J = 6 Hz, 6H), 0.88 (t, J = 6 Hz, 4H). 13C NMR (75 MHz, CDCl3) δ 
178.0 (C=O), 173.9 (C=O), 169.1 (C=O), 147.1 (Ar-C), 146.1 (Ar-C), 137.0 (Ar-C), 
132.8 (Ar-C), 127.1 (Ar-C), 117.8 (Ar-C), 52.1, 50.2 , 47.2 (OCH3), 45.4, 40.0, 37.6, 
37.2, 34.4, 33.6, 32.4, 31.9, 29.4, 29.0, 27.2, 26.3, 26.1, 25.1, 23.1, 22.9, 22.7, 21.0, 
18.6, 16.3 cm-1. IR (ATR) 3368 (N-H), 2924 (C-H), 1746 (C=O), 1642 (C=O) 1206, 
914. UPLC-HRMS m/z: calcd. for C32H47NO5 526.3488 [M+H]+, found 526.3532. 
 
12-Hydroxy-N-(abiet-8,11,13-trien-18-oyl) cyclohexyl-L-alanine (101). Compound 
100 (0.600 g, 1.14 mmol) was dissolved in THF:MeOH 1:1 (14.4 mL), under magnetic 
stirring at 0 °C. A 4 M aqueous solution of NaOH (13 mL, 52 mmol, 46 equiv.) was 
added dropwise. The mixture was left to agitate for 1 hour 15 minutes, after which the 
reaction was quenched by the addition of a 4 M aqueous solution of HCl dropwise until 
the pH reached 6-7. The mixture was concentrated under reduced pressure, diluted with 
water (20 mL) and extracted with diethyl ether (3 × 40 mL). The organic phases were 
combined and washed with a 1 M aqueous solution of HCl (30 mL), water (30 mL) and 
brine (30 mL) then dried with Na2SO4. The mixture was filtered, evaporated under 
reduced pressure and purified by silica gel column chromatography (SNAP 50 G, n-
heptane / EtOAC, 1/2). After evaporation of solvents, yellow solid was obtained (506 
mg, 98%). 
 
1H NMR (300 MHz, CDCl3) δ 6.81 (s, 1H, Ar-H), 6.62 (s, 1H, Ar-H), 6.11 (d, J = 6 Hz, 
1H, NH), 4.62 (m, 1H), 3.11 (m, 1H), 2.80 (t, J = 3 Hz, 2H), 1.64 (m, 16H), 1.29 (s, 
3H), 1.23 (d, J = 6 Hz, 12 Hz). 13C NMR (75 MHz, CDCl3) δ 179.1 (C=O), 177.0 
(C=O), 150.8 (Ar-C), 147.8 (Ar-C), 131.8 (Ar-C), 126.8 (Ar-C), 126.7 (Ar-C), 110.8 
(Ar-C), 50.5, 47.3, 45.6, 39.3, 37.9, 37.1, 34.4, 33.6, 32.3, 29.1, 26.8, 26.3, 26.2, 26.0, 
25.1, 22.7, 22.5, 21.2, 18.7, 16.4. IR (ATR) 2925 (C-H), 1720 (C=O), 1626 (C=O), 
1510, 1209, 886 cm-1. UPLC-HRMS m/z: calcd. for C29H43NO4 470.3226 [M+H]+, 
found 470.3276. 
 
tert-Butyl (abiet-8,11,13-trien-18-oyl) carboxylate (102). 3 (0.500 g, 1.66 mmol), 
conc. H2SO4 (13 mg, 0.13 mmol, 0.08 equiv.) and tert-butyl acetoacetate (1.71 g, 10.80 
mmol, 6.5 equiv.) were added to a glass pressure tube. The reaction vessel was sealed at 
rt for 24 hours, after which conc H2SO4 (0.12 g, 1.22 mmol, 0.73 equiv.) and anhydrous 
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MgSO4 (0.48 g, 3.03 mmol, 1.82 equiv.) were added. The reaction mixture was left to 
agitate at rt for 144 hours after which it was stopped by the addition of diethyl ether 
(100 mL) and a 1.25% aqueous solution of NaOH (30 mL). The organic extract was 
washed with brine (50 mL), dried over Na2SO4, and concentrated to yield 102 as yellow 
oil (286 mg, 48%). 
 
1H NMR (300 MHz, CDCl3) δ 7.18 (d, J = 9 Hz, 1H, Ar-H), 7.51 (m, 1H, Ar-H), 6.89 
(s, 1H, Ar-H), 2.84 (m, 3H), 1.97 (m, 11H), 1.43 (s, 9H, 3CH3), 1.24 (s, 2H), 1.22 (d, J 
= 3 Hz, 5H), 1.20 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 177.6 (C=O), 147.1 (Ar-C), 
145.6 (Ar-C), 134.8 (Ar-C), 126.9 (Ar-C), 124.3 (Ar-C), 123.9 (Ar-C), 79.7 (OCH3), 
47.9, 45.0, 38.1, 37.0, 36.4, 33.4, 30.5, 28.0, 25.3, 23.9, 21.6, 18.7, 16.4. IR (ATR) 
2930 (C-H), 1716 (C=O), 1256, 1159, 1128, 853 cm-1. 
 
Abietane-18 carboxylic acid (103). Compound 1 (0.350 g, 1.16 mmol) was dissolved 
in MeOH (8 mL). The resulting solution was flushed with one balloon of argon after 
which 10 wt.% Pd/C (30 mg) was added. Under stirring the mixture was flushed with 
another balloon of argon then a small balloon of H2 and the reaction mixture was left to 
agitate for 24 hours, at rt. The mixture was filtered once through a pad of Celite, 
evaporated under reduced pressure and purified by silica gel column chromatography 
(SNAP 50 G, n-hexane / EtOAC, 2/1). After evaporation of solvents, a white solid was 
obtained (45 mg, 13%). 
 
1H NMR (300 MHz, CDCl3) δ 1.74 (m, 17H), 1.19 (d, J = 3 Hz, 3H), 1.00 (m, 4H), 0.85 
(m, 9H). 13C NMR (75 MHz, CDCl3) δ 185.2 (C=O), 56.1, 49.6, 47.4, 43.7, 37.1, 36.5, 
36.1, 35.2, 32.8, 32.0, 29.9, 24.8, 24.4, 20.7, 20.6, 19.8, 18.0, 14.5. IR (ATR) 2926 (C-
H), 1691 (C=O), 1454, 1275, 942 cm-1. 
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